Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
30 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 54(3); July 2022
Prev issue Next issue
Review Article
Prognostication of the Last Days of Life
Masanori Mori, Tatsuya Morita, Eduardo Bruera, David Hui
Cancer Res Treat. 2022;54(3):631-643.   Published online March 30, 2022
DOI: https://doi.org/10.4143/crt.2021.1573
AbstractAbstract PDFPubReaderePub
Accurate prediction of impending death (i.e., last few days of life) is essential for terminally-ill cancer patients and their families. International guidelines state that clinicians should identify patients with impending death, communicate the prognosis with patients and families, help them with their end-of-life decision-making, and provide sufficient symptom palliation. Over the past decade, several national and international studies have been conducted that systematically investigated signs and symptoms of impending death as well as how to communicate such a prognosis effectively with patients and families. In this article, we summarize the current evidence on prognostication and communication regarding the last days of life of patients with cancer, and future directions of clinical research.

Citations

Citations to this article as recorded by  
  • Prevalence of Triggers and Patient Harm Identified by Global Trigger Tool in Specialized Palliative Care
    Olav Magnus S. Fredheim, Espen Klingenberg, Anne Karin Lindahl
    Journal of Palliative Medicine.2024; 27(6): 742.     CrossRef
  • Uso degli antibiotici nel fine vita
    Matteo Moroni, Massimo Melo, Raffaella Antonione, Massimo Fantoni, Roberto Luzzati, Massimiliano Lanzafame, Rita Murri, Fabio Gilioli, Francesco Dentali, Dario Manfellotto, Biancamaria Fraccaro, Luigi Patil
    Italian Journal of Medicine.2024;[Epub]     CrossRef
  • Using Performance Status to Identify Risk of Acute Care Transfer in Inpatient Cancer Rehabilitation
    Keara McNair, Amanda Botticello, Michael D. Stubblefield
    Archives of Physical Medicine and Rehabilitation.2024; 105(5): 947.     CrossRef
  • Indian Society of Critical Care Medicine and Indian Association of Palliative Care Expert Consensus and Position Statements for End-of-life and Palliative Care in the Intensive Care Unit
    Sudeep Gupta, Arun Kumar, Roli Mathur, Roop Gursahani, Sushma Bhatnagar, Jayita Deodhar, Prashant Nasa, Raj Kumar Mani, Naveen Salins, Priyadarshini Kulkarni, Srinagesh Simha, Jigeeshu V Divatia, Sheila N Myatra, Dhvani Mehta, Rajani S Bhat, Savita Butola
    Indian Journal of Critical Care Medicine.2024; 28(3): 200.     CrossRef
  • Comparison of Prognostic Abilities of Palliative Prognostic Index, Laboratory Prognostic Score, and Palliative Prognostic Score
    Norihiro Yuasa, Natsuko Kawai, Junichi Takamizawa
    Journal of Pain and Symptom Management.2024; 68(2): 153.     CrossRef
  • Management of Infections in Palliative Care Patients at the End-of-Life and Active Process of Death: A Brazilian Retrospective Study
    Isabela Fernandes de Aguiar Tonetto, Angelita Maria Stabile, Dieyeni Yuki Kobayasi, Rita de Cássia Quaglio, Ana Carolina de Souza, Fabiana Bolela
    Palliative Medicine Reports.2024; 5(1): 324.     CrossRef
  • Fatores Associados ao Karnofsky Performance Status e sua Trajetória no Último Mês de Vida em Pacientes com Câncer Terminal
    Andrezza Helena Regadas Muniz, Karla Santos da Costa Rosa, Juliana Miranda Dutra de Resende, Simone Garruth dos Santos Machado Sampaio, Livia Costa de Oliveira
    Revista Brasileira de Cancerologia.2023;[Epub]     CrossRef
  • ‘It’s not just about me’: a qualitative study of couples’ narratives about home death when one of the partners is dying of cancer
    Margareta Aurén-Møkleby, Lisbeth Thoresen, Anne Marit Mengshoel, Kari N. Solbrække, Gunvor Aasbø
    Palliative Care and Social Practice.2023;[Epub]     CrossRef
  • Appetite and its association with mortality in patients with advanced cancer – a Post-hoc Analysis from the Palliative D-study
    Charlotte Goodrose-Flores, Stephanie E. Bonn, Caritha Klasson, Maria Helde Frankling, Ylva Trolle Lagerros, Linda Björkhem-Bergman
    BMC Palliative Care.2023;[Epub]     CrossRef
  • Overtreatment in end-of-life care: how can we do better?
    Linda Björkhem-Bergman
    Acta Oncologica.2022; 61(12): 1435.     CrossRef
  • 9,159 View
  • 585 Download
  • 8 Web of Science
  • 10 Crossref
Close layer
Special Articles
Palliative Sedation in End-of-Life Patients in Eastern Asia: A Narrative Review
Seung Hun Lee, Jung Hye Kwon, Young-Woong Won, Jung Hun Kang
Cancer Res Treat. 2022;54(3):644-650.   Published online April 19, 2022
DOI: https://doi.org/10.4143/crt.2022.187
AbstractAbstract PDFPubReaderePub
Although palliative sedation (PS) is a common practice in the palliative care of cancer patients in Western countries, there is little related research on the practice in Korea. PS can be classified into several categories according to sedation level and continuity. PS is clearly distinct from euthanasia. While euthanasia is illegal and regarded as unethical in Korea, there is little ethical and legal controversy about PS in terms of the doctrine of double effect. Most studies have asserted that PS does not shorten the survival of terminal cancer patients. Since preference for PS heavily depends on stakeholder value, it should be preceded by shared decision-making through full communication among the patient, family members, and medical team. This is a narrative review article analyzing previous studies, especially from the three Eastern Asian countries, Korea, Japan and Taiwan, which share similar cultures compared with Western countries. Practical issues concerning PS—for example, prevalence, type and dosage of medications, salvage medication, timing of its initiation, and assessment—are described in detail.

Citations

Citations to this article as recorded by  
  • Ethical and moral principles for oncology healthcare workers: A brief report from a Bioethics consortium emphasizing on need for education
    Manjeshwar S. Baliga, Vijaya Marakala, Lal P. Madathil, Thomas George, Russell F. D’souza, Princy L. Palatty
    Journal of Education and Health Promotion.2024;[Epub]     CrossRef
  • Continuous Sedation in Palliative Care in Portugal: A Prospective Multicentric Study
    José António Ferraz-Gonçalves, Alice Flores, Ana Abreu Silva, Ana Simões, Carmen Pais, Clarisse Melo, Diana Pirra, Dora Coelho, Lília Conde, Lorena Real, Madalena Feio, Manuel Barbosa, Maria de Lurdes Martins, Marlene Areias, Rafael Muñoz-Romero, Rita Cun
    Journal of Palliative Care.2024;[Epub]     CrossRef
  • Survival Outcomes in Palliative Sedation Based on Referring Versus On-Call Physician Prescription
    Cristina Lojo-Cruz, Juan Mora-Delgado, Víctor Rivas Jiménez, Fernando Carmona Espinazo, Juan-Bosco López-Sáez
    Journal of Clinical Medicine.2023; 12(16): 5187.     CrossRef
  • Current Status and Future Directions of Research on Palliative Sedation
    In Cheol Hwang
    The Korean Journal of Hospice and Palliative Care.2022; 25(4): 193.     CrossRef
  • Legislation concerning Physician-assisted Suicide in Korea
    Younsuck KOH
    Korean Journal of Medical Ethics.2022; 25(4): 313.     CrossRef
  • 5,606 View
  • 170 Download
  • 3 Web of Science
  • 5 Crossref
Close layer
Psychological Aspects of Care in Cancer Patients in the Last Weeks/Days of Life
Sujin Ann-Yi, Eduardo Bruera
Cancer Res Treat. 2022;54(3):651-660.   Published online June 28, 2022
DOI: https://doi.org/10.4143/crt.2022.116
AbstractAbstract PDFPubReaderePub
Palliative care is comprised of an interdisciplinary team (IDT) approach with members from different disciplines who collaboratively work together to reduce multidimensional components of pain and suffering and improve quality of life for patients coping with a terminal illness. Psychosocial team members are integral to the palliative care IDT and provide expertise in assessment and empirically validated interventions to address psychological distress. The following paper will provide a review of different facets of psychological distress experienced by advanced cancer patients such as psychological disorders, existential distress, spiritual distress, caregiver distress, parental distress, and grief. Finally, an overview of commonly used screening and assessment tools as well as psychological interventions relevant for the palliative care population is presented.

Citations

Citations to this article as recorded by  
  • Psychosocial Distress Screening Among Interprofessional Palliative Care Teams: A Narrative Review
    Chelsea K. Brown, Cara L. Wallace
    Journal of Social Work in End-of-Life & Palliative Care.2024; 20(2): 161.     CrossRef
  • Diagnostic and therapeutic strategies in pancreatic adenosquamous carcinoma: Molecular and clinical insights in managing metastatic disease
    Nathaniel Grabill, Mena Louis, Mariah Cawthon, Claudia Gherasim, James Chambers
    Radiology Case Reports.2024; 19(12): 6016.     CrossRef
  • Acceptance and Commitment Therapy (ACT) for people with advanced progressive illness, their caregivers and staff involved in their care: A scoping review
    Tilly Gibson Watt, David Gillanders, Juliet A Spiller, Anne M Finucane
    Palliative Medicine.2023; 37(8): 1100.     CrossRef
  • Palliative care competence among medical students
    Úrsula Bueno do Prado Guirro, Carla Corradi Perini, Luís Otávio Zatorre Fileno, Gustavo Belam Fioravanti, José Eduardo de Siqueira
    Revista Bioética.2023;[Epub]     CrossRef
  • Competencias en cuidados paliativos entre los estudiantes de medicina
    Úrsula Bueno do Prado Guirro, Carla Corradi Perini, Luís Otávio Zatorre Fileno, Gustavo Belam Fioravanti, José Eduardo de Siqueira
    Revista Bioética.2023;[Epub]     CrossRef
  • Competências em cuidados paliativos entre estudantes do curso de medicina
    Úrsula Bueno do Prado Guirro, Carla Corradi Perini, Luís Otávio Zatorre Fileno, Gustavo Belam Fioravanti, José Eduardo de Siqueira
    Revista Bioética.2023;[Epub]     CrossRef
  • 8,759 View
  • 234 Download
  • 3 Web of Science
  • 6 Crossref
Close layer
Management of Physical Symptoms in Patients with Advanced Cancer during the Last Weeks and Days of Life
Ahsan Azhar, David Hui
Cancer Res Treat. 2022;54(3):661-670.   Published online June 30, 2022
DOI: https://doi.org/10.4143/crt.2022.143
AbstractAbstract PDFPubReaderePub
Patients with advanced cancer are faced with many devastating symptoms in the last weeks and days of life, such as pain, delirium, dyspnea, bronchial hypersecretions (death rattle) and intractable seizures. Symptom management in the last weeks of life can be particularly challenging because of the high prevalence of delirium complicating symptom assessment, high symptom expression secondary to psychosocial and spiritual factors, limited life-expectancy requiring special considerations for prognosis-based decision-making, and distressed caregivers. There is a paucity of research involving patients in the last weeks of life, contributing to substantial variations in clinical practice. In this narrative review, we shall review the existing literature and provide a practical approach to in-patient management of several of the most distressing physical symptoms in the last weeks to days of life.

Citations

Citations to this article as recorded by  
  • Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index
    Rishi Sachdev, Galen Shearn-Nance, Long Vu, Wyatt P. Bensken, Sara L. Douglas, Siran M. Koroukian, Johnie Rose
    Journal of Geriatric Oncology.2024; 15(2): 101706.     CrossRef
  • 6,128 View
  • 162 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Original Articles
General
Functional Impairments in the Mental Health, Depression and Anxiety Related to the Viral Epidemic, and Disruption in Healthcare Service Utilization among Cancer Patients in the COVID-19 Pandemic Era
Kyumin Kim, Harin Kim, Joohee Lee, Inn-Kyu Cho, Myung Hee Ahn, Ki Young Son, Jeong Eun Kim, Hee Jeong Kim, Sang Min Yoon, So Hee Kim, Moon Jung Kwon, Hwa Jung Kim, Su-Jin Koh, Seyoung Seo, Seockhoon Chung
Cancer Res Treat. 2022;54(3):671-679.   Published online September 17, 2021
DOI: https://doi.org/10.4143/crt.2021.585
AbstractAbstract PDFPubReaderePub
Purpose
Literature is scarce regarding cancer care utilization during the massive outbreak of coronavirus disease 2019 (COVID-19) in the Republic of Korea. We investigated functional impairments in mental health and their relationships with depression, anxiety regarding the viral epidemic, and disruptions in healthcare service utilization among cancer patients in the COVID-19 pandemic era.
Materials and Methods
We used an online survey with questions related to the disturbances faced by patients with cancer in utilizing healthcare services in the pandemic era. Current mental health status was assessed using the Work and Social Adjustment Scale (WSAS), Stress and Anxiety to Viral Epidemics-6 (SAVE-6) scale, Patient Health Questionnaire-9 (PHQ-9), Insomnia Severity Index (ISI), Brief Resilience Scale (BRS), Cancer-Related Dysfunctional Beliefs about Sleep Scale (C-DBS), and Fear of COVID-19 over Cancer (FCC).
Results
Among the 221 responders, 95 (43.0%) reported disruptions in healthcare service utilization during the COVID-19 pandemic. Logistic regression analysis revealed that functional impairment in the mental health of these patients was expected due to disruptions in healthcare service utilization, high levels of depression, anxiety regarding the viral epidemic, fear of COVID over cancer, and low resilience. Mediation analysis showed that patient resilience and cancer-related dysfunctional beliefs about sleep partially mediated the effects of viral anxiety on functional impairment.
Conclusion
In this pandemic era, patients with cancer experience depression, anxiety regarding the viral epidemic, and disruptions in healthcare service utilization, which may influence their functional impairments in mental health.

Citations

Citations to this article as recorded by  
  • Prevalence of depressive symptoms and correlates among individuals who self-reported SARS-CoV-2 infection after optimizing the COVID-19 response in China
    Liangjia Wei, Jiao Qin, Zhifeng Lin, Xinju Huang, Jinfeng He, Dee Yu, Fei Zhang, Sisi Li, Ping Cen, Mu Li, Tong Luo, Rongjing Zhang, Shanmei Zhong, Cai Qin, Zeyu Li, Yuan Yang, Huiqi Pan, Mengdi Zhao, Xiaoqiong Wu, Junjun Jiang, Hao Liang, Li Ye, Bingyu L
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Evaluation of mental health of students in healthcare education programs at Qatar University
    Ola Hayk, Abdulla Mansoor, Shahd Al-Najdi, Alaa Daud, Rula Shami, Najah Al-Hashimi, Kamran Ali
    MedEdPublish.2024; 14: 37.     CrossRef
  • Inpatient Hospice Care in Korea during the COVID-19 Pandemic: A Preliminary Study
    Youn Seon Choi, Sun Wook Hwang, In Cheol Hwang
    Journal of Hospice and Palliative Care.2024; 27(2): 82.     CrossRef
  • The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations
    Amanda L King, Kayla N Roche, Elizabeth Vera, Valentina Pillai, Lily Polskin, Alvina A Acquaye-Mallory, Lisa Boris, Eric Burton, Anna Choi, Ewa Grajkowska, Heather E Leeper, Marissa Panzer, Marta Penas-Prado, Jennifer Reyes, Solmaz Sahebjam, Brett J Theel
    Neuro-Oncology Practice.2024;[Epub]     CrossRef
  • Risk factors for heightened COVID‐19‐Related anxiety among breast cancer patients
    Yash B. Shah, Stephanie Kjelstrom, Diana Martinez, Adam Leitenberger, Donna‐Marie Manasseh, Melissa Bollmann‐Jenkins, Ann Partridge, Virginia Kaklamani, Rowen Chlebowski, Sharon Larson, Marisa Weiss
    Cancer Medicine.2023; 12(3): 3577.     CrossRef
  • Discrepancy between desired time in bed and desired total sleep time in patients with cancer: The DBST index and its relationship with insomnia severity and sleep onset latency
    Eulah Cho, Jaeeun Song, Joohee Lee, Inn-Kyu Cho, Dongin Lee, Hayun Choi, Harin Kim, Seockhoon Chung
    Frontiers in Psychiatry.2023;[Epub]     CrossRef
  • Health-related quality of life and depressive symptoms of patients with chronic diseases and the general population before and during the COVID-19 pandemic in Korea
    Yeeun Park, Kyong Park
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • A study of COVID anxiety, spiritual well-being and resilience levels in patients with cancer undergoing chemotherapy during the COVID-19 pandemic: a cross-sectional study in the south of Iran
    Zahra Khiyali, Zeinab Naderi, Mohammadkazem Vakil, Hajar Ghasemi, Azizallah Dehghan, Mostafa Bijani
    BMC Psychology.2023;[Epub]     CrossRef
  • Does Viral Anxiety Influence the Insomnia Severity Among Patients With Insomnia Disorder During COVID-19 Pandemic?
    Jana Sleiman, Eulah Cho, Dongin Lee, Inn-Kyu Cho, Seockhoon Chung, Omer Faruk Uygur
    Sleep Medicine Research.2023; 14(1): 25.     CrossRef
  • Associations of psychological status and ultrasonic characteristics of thyroid nodules in adults during the COVID-19 pandemic
    Zhengwu Lei, Zhongxiang He, Ying Mei, Xiaoya Qi, Pingping Yu, Guoqiong Xu, Hongfeng Cheng, Ruixue Bai, Jing Deng
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • The Impact of COVID-19 on Psychiatric Health in the Korean Population
    Sheng-Min Wang, Sung-Hwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bahk
    Clinical Psychopharmacology and Neuroscience.2023; 21(3): 410.     CrossRef
  • Adherence to Physical Distancing and Health Beliefs About COVID-19 Among Patients With Cancer
    Sajida Fawaz Hammoudi, Oli Ahmed, Hoyoung An, Youjin Hong, Myung Hee Ahn, Seockhoon Chung
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic
    Hyuk Joo Lee, Cheolkyung Sin, Hyeyeong Kim, Hyeon-Su Im, Jae-Cheol Jo, Yoo Jin Lee, Youjin Kim, Junseok Ahn, Soyoung Yoo, Su-Jin Koh, Seockhoon Chung
    Psychiatry Investigation.2023; 20(12): 1204.     CrossRef
  • The role of social support and resilience in the mental health impact of the COVID-19 pandemic among healthcare workers in Spain
    Esther Ortiz-Calvo, Gonzalo Martínez-Alés, Roberto Mediavilla, Elisabeth González-Gómez, Eduardo Fernández-Jiménez, María-Fe Bravo-Ortiz, Berta Moreno-Küstner
    Journal of Psychiatric Research.2022; 148: 181.     CrossRef
  • The Validation Study of the Stress and Anxiety to Viral Epidemics−6 Scale Among Patients With Cancer in the COVID-19 Pandemic
    Hyeyeong Kim, Harin Kim, Hyuk Joo Lee, Eulah Cho, Su-Jin Koh, Oli Ahmed, Seockhoon Chung
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Resilience, Social Support, and Anxious Preoccupation in Patients with Advanced Cancer during COVID-19 Pandemic
    Veronica Velasco-Durantez, Paula Jimenez-Fonseca, Carla M. Martín Abreu, Ismael Ghanem, Manuel González Moya, Elena Asensio, María J. Corral, Adan Rodriguez-Gonzalez, Mireia Gil-Raga, Alberto Carmona-Bayonas, Caterina Calderon
    Cancer Investigation.2022; 40(6): 475.     CrossRef
  • Mental Health in Postoperative Thyroid Patients During the COVID-19 Pandemic
    Shijie Yang, Xiequn Xu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Effect of Cancer-Related Dysfunctional Beliefs About Sleep on Fear of Cancer Progression in the Coronavirus Pandemic
    Harin Kim, Inn-Kyu Cho, Dongin Lee, Kyumin Kim, Joohee Lee, Eulah Cho, C. Hyung Keun Park, Seockhoon Chung
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Insomnia Mediate the Influence of Reassurance-Seeking Behavior and Viral Anxiety on Preoccupation With COVID-19 Among the General Population
    Eulah Cho, Dongin Lee, Inn-Kyu Cho, Joohee Lee, Junseok Ahn, Young Rong Bang
    Sleep Medicine Research.2022; 13(2): 68.     CrossRef
  • Reliability and Validity of Dysfunctional Beliefs About Sleep-2 (DBS-2), an Ultra-brief Rating Scale for Assessing Dysfunctional Thoughts About Sleep
    Kyumin Kim, Seockhoon Chung, Eulah Cho, Jung Mun Choi, Dongin Lee, Inn-Kyu Cho
    Sleep Medicine Research.2022; 13(3): 165.     CrossRef
  • 9,185 View
  • 276 Download
  • 18 Web of Science
  • 20 Crossref
Close layer
Emergency Department Utilization of Adult Cancer Patient in Korea: A Nationwide Population-Based Study, 2017-2019
Hye Sook Min, Hye Jung Chang, Ho Kyung Sung
Cancer Res Treat. 2022;54(3):680-689.   Published online September 17, 2021
DOI: https://doi.org/10.4143/crt.2021.699
AbstractAbstract PDFPubReaderePub
Purpose
The current study aimed to identify the overall characteristics of cancer-related emergency department (ED) visits by adult in Korea, including analyses of factors associated with ED stay time and outcomes nationwide.
Materials and Methods
We collected data on cancer-related ED visits from the National Emergency Department Information System (NEDIS) database between 2017 and 2019.
Results
ED visits by cancer patients comprised 5.5% (667,935 visits) of total ED visits from 2017 to 2019, which was slightly higher than in other counties. Patients with cancer who visited the ED were over 50 years old, the majority being males, and patients with cancer visited EDs in certified tertiary hospitals more frequently than patients without cancer. In multivariate analyses, the adjusted odds ratio for a length of stay more than 8 hours in the ED of certified tertiary hospitals was 126.34 (95% confidence interval, 1.422 to 1.460) when compared to hospitals. Nevertheless, the longer the patients stayed in the ED, the more likely they were to be admitted.
Conclusion
The longer ED stay and higher proportion of cancer patient hospitalizations suggest that cancer patients visit ED to be admitted as well as to receive acute care. The frequency of ED visits and admission may be adjusted to some extent depending on outpatient education, such as self-management of symptoms and situations. Improving cancer care in local communities should be met though provisions such as linking treatment between hospitals or supplying appropriate medical personnel, even for the efficient use of ED resources in hospitals.

Citations

Citations to this article as recorded by  
  • Trends in emergency department visits for emergency care–sensitive conditions before and during the COVID-19 pandemic: a nationwide study in Korea, 2019–2021
    Seonji Kim, Ho Kyung Sung, Jeehye Lee, Eunsil Ko, Seong Jung Kim
    Clinical and Experimental Emergency Medicine.2024; 11(1): 88.     CrossRef
  • Impact of the early phase of the COVID-19 pandemic on emergency department-to-intensive care unit admissions in Korea: an interrupted time-series analysis
    Kyung-Shin Lee, Changwoo Han, Hye Sook Min, Jeehye Lee, Seok Hwa Youn, Younghwan Kim, Jae Young Moon, Young Seok Lee, Su Jin Kim, Ho Kyung Sung
    BMC Emergency Medicine.2024;[Epub]     CrossRef
  • Impact of the Early COVID-19 Pandemic on Emergency Department Visits of Adult Cancer Patients With Fever or Respiratory Symptoms: A Korean Nationwide Population-Based Study, 2016–2020
    Kyung Shin Lee, Ho Kyung Sung, Youn Young Choi, Changwoo Han, Hye Sook Min
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Clinical, Demographic Characteristics and Short-Term Prognosis of Cancer Patients Presenting to the Emergency Department
    Şimşek Çelik, Pelin Çelik
    Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi.2024; 6(2): 284.     CrossRef
  • Diagnosis of cancer in the Emergency Department: A scoping review
    Alix Delamare Fauvel, Jason J. Bischof, Raquel E. Reinbolt, Veronica K. Weihing, Edward W. Boyer, Jeffrey M. Caterino, Henry E. Wang
    Cancer Medicine.2023; 12(7): 8710.     CrossRef
  • Factors Influencing Posttraumatic Growth Among Primary Caregivers of Patients with Oncologic Emergencies in Taiwan Intensive Care Units: A Cross-Sectional Study of Patient–Caregiver Dyads
    Ya-Hsin Lo, Chih-Hsi Kuo, Ching-Ching Tsai, Shu-Ching Chen
    Seminars in Oncology Nursing.2023; 39(5): 151497.     CrossRef
  • Trends in emergency department visits for suicide attempts before and during the COVID-19 pandemic in Korea: A nationwide study, 2016–2021
    Seonji Kim, Ho Kyung Sung, Taehui Kim, Sung-keun Ko, SeongJung Kim, Jin-Hee Lee
    Journal of Affective Disorders.2023; 331: 184.     CrossRef
  • The severity of clinical symptoms according to cancer diagnosis in fever patients visiting the emergency department: a retrospective analysis
    Eun Seam Lee, Purum Kang, You Kyoung Shin, Geun Hee Seol
    Journal of Korean Biological Nursing Science.2023; 25(2): 105.     CrossRef
  • Drivers of Emergency Department Use Among Oncology Patients in the Era of Novel Cancer Therapeutics: A Systematic Review
    Lauren Fleshner, Andrew Lagree, Audrey Shiner, Marie Angeli Alera, Mateusz Bielecki, Robert Grant, Alex Kiss, Monika K Krzyzanowska, Ivy Cheng, William T Tran, Sonal Gandhi
    The Oncologist.2023; 28(12): 1020.     CrossRef
  • Epidemiologic trends of patients who visited nationwide emergency departments: a report from the National Emergency Department Information System (NEDIS) of Korea, 2018–2022
    Hyun Ho Yoo, Young Sun Ro, Eunsil Ko, Jin-Hee Lee, So-hyun Han, Taerim Kim, Tae Gun Shin, Seongjung Kim, Hansol Chang
    Clinical and Experimental Emergency Medicine.2023; 10(S): S1.     CrossRef
  • Aggressiveness of care in the last days of life in the emergency department of a tertiary hospital in Korea
    Jung Sun Kim, Sun Young Lee, Min Sung Lee, Shin Hye Yoo, Jeongmi Shin, Wonho Choi, Yejin Kim, Hyung Sook Han, Jinui Hong, Bhumsuk Keam, Dae Seog Heo
    BMC Palliative Care.2022;[Epub]     CrossRef
  • Suicide attempt-related emergency department visits among adolescents: a nationwide population-based study in Korea, 2016–2019
    Kyung-Shin Lee, Daesung Lim, Jong-Woo Paik, Youn Young Choi, Jaehyun Jeon, Ho Kyung Sung
    BMC Psychiatry.2022;[Epub]     CrossRef
  • The impact of COVID-19 on cancer care in a tertiary hospital in Korea: possible collateral damage to emergency care
    Shin Hye Yoo, Jin-Ah Sim, Jeongmi Shin, Bhumsuk Keam, Jun-Bean Park, Aesun Shin
    Epidemiology and Health.2022; 44: e2022044.     CrossRef
  • Patient and hospital characteristics predict prolonged emergency department length of stay and in-hospital mortality: a nationwide analysis in Korea
    Kyung-Shin Lee, Hye Sook Min, Jae Young Moon, Daesung Lim, Younghwan Kim, Eunsil Ko, You Sun Kim, Joohae Kim, Jeehye Lee, Ho Kyung Sung
    BMC Emergency Medicine.2022;[Epub]     CrossRef
  • 6,264 View
  • 278 Download
  • 14 Web of Science
  • 14 Crossref
Close layer
CNS cancer
Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma
Hoon Gi Kim, Minseok S. Kim, Young Sam Lee, Eun Hee Lee, Dae Cheol Kim, Sung-Hun Lee, Young Zoon Kim
Cancer Res Treat. 2022;54(3):690-708.   Published online November 17, 2021
DOI: https://doi.org/10.4143/crt.2021.1121
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to investigate the methylation status of major histone modification sites in primary central nervous system lymphoma (PCNSL) samples and examine their prognostic roles in patients with PCNSL.
Materials and Method
Between 2007 and 2020, 87 patients were histopathologically diagnosed with PCNSL. We performed immunohistochemical staining of the formalin-fixed paraffin-embedded samples of PCNSL for major histone modification sites, such as H3K4, H3K9, H3K27, H3K14, and H3K36. After detection of meaningful methylation sites, we examined histone modification enzymes that induce methylation or demethylation at each site using immunohistochemical staining. The meaningful immunoreactivity was validated by western blotting using fresh tissue of PCNSL.
Results
More frequent recurrences were found in hypomethylation of H3K4me3 (p=0.004) and hypermethylation of H3K27me2 (p<0.001) and H3K27me3 (p=0.002). These factors were also statistically related to short PFS and overall survival in the univariate and multivariate analyses. Next, histone modification enzymes inducing the demethylation of H3K4 (lysine-specific demethylase-1/2 and Jumonji AT-rich interactive domain [JARID] 1A-D]) and methylation of H3K27 (enhancer of zeste homolog [EZH]-1/2) were immu- nohistochemically stained. Among them, the immunoreactivity of JARID1A inversely associated with the methylation status of H3K4me3 (R2=-1.431), and immunoreactivity of EZH2 was directly associated with the methylation status of H3K27me2 (R2=0.667) and H3K27me3 (R2=0.604). These results were validated by western blotting in fresh PCNSL samples.
Conclusion
Our study suggests that hypomethylation of H3K4me3 and hypermethylation of H3K27me2 and H3K27me3 could be associated with poor outcomes in patients with PCNSL and that these relationships are modified by JARID1A and EZH2.

Citations

Citations to this article as recorded by  
  • Updates of primary central nervous system lymphoma
    Jiaying Wu, Delian Zhou, Xiaojian Zhu, Yicheng Zhang, Yi Xiao
    Therapeutic Advances in Hematology.2024;[Epub]     CrossRef
  • 3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells
    Mika Hosokawa, Sekai Tetsumoto, Mirano Yasui, Yusuke Kono, Ken-ichi Ogawara
    Biochemical and Biophysical Research Communications.2023; 677: 26.     CrossRef
  • Extranodal lymphoma: pathogenesis, diagnosis and treatment
    Hua Yang, Yang Xun, Chao Ke, Kensuke Tateishi, Hua You
    Molecular Biomedicine.2023;[Epub]     CrossRef
  • Diagnostic and Therapeutic Perspectives Associated to Cobalamin-Dependent Metabolism and Transcobalamins’ Synthesis in Solid Cancers
    Valentin Lacombe, Guy Lenaers, Geoffrey Urbanski
    Nutrients.2022; 14(10): 2058.     CrossRef
  • Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies
    Isaias Hernández-Verdin, Andrea Morales-Martínez, Khê Hoang-Xuan, Agustí Alentorn
    Current Opinion in Neurology.2022; 35(6): 779.     CrossRef
  • 6,308 View
  • 173 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Head and Neck cancer
Effect of National Oral Health Screening Program on the Risk of Head and Neck Cancer: A Korean National Population-Based Study
Chan Woo Wee, Hyo-Jung Lee, Jae-Ryun Lee, Hyejin Lee, Min-Jeong Kwoen, Woo-Jin Jeong, Keun-Yong Eom
Cancer Res Treat. 2022;54(3):709-718.   Published online October 22, 2021
DOI: https://doi.org/10.4143/crt.2021.834
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Poor oral health is associated with head and neck cancer (HNC). We evaluated whether a national oral health screening program (OHSP) could reduce the risk of HNC.
Materials and Methods
Data from 408,247 healthy individuals aged ≥ 40 years from the National Health Insurance System-National Health Screening program during 2003 and 2004 in Korea were analyzed. The risk of HNC was compared between subjects who underwent OHSP (HEALS-Dental+, n=165,292) and routine health check-ups only (HEALS-Dental‒, n=242,955). The impact of individual oral health-related factors on HNC risk was evaluated in HEALS-Dental+.
Results
A total of 1,650 HNC cases were diagnosed. The 10-year HNC-free rate was 99.684% with a median follow-up of 11 years. The risk of all HNC (hazard ratio [HR], 1.16; 95% confidence interval [CI], 1.03 to 1.29; p=0.011) and oropharyngeal cancer (HR, 1.48; 95% CI, 1.13 to 1.94; p=0.005) was significantly higher in HEALS-Dental‒ than in HEALS-Dental+. In HEALS-Dental+, oral cavity cancer was marginally reduced (p=0.085), and missing teeth was a significant factor for HNC (HR, 1.24; 95% CI, 1.02 to 1.50; p=0.032). Toothbrushing was a significant factor in univariate analysis (p=0.028), but not in multivariate analysis (p=0.877).
Conclusion
The National OHSP significantly reduced the long-term HNC risk, particularly the incidence of oropharyngeal cancer. Routine OHSP should be considered at the population level.

Citations

Citations to this article as recorded by  
  • Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo
    Takumi Sato, Yasumasa Kakei, Takumi Hasegawa, Masahiko Kashin, Shun Teraoka, Akinobu Yamaguchi, Ryohei Sasaki, Masaya Akashi
    Cancers.2023; 15(23): 5697.     CrossRef
  • 6,102 View
  • 137 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
Hye Ryeon Kim, Su Jin Lee, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Han-Sin Jeong, Man Ki Chung, Myung-Ju Ahn
Cancer Res Treat. 2022;54(3):719-727.   Published online November 1, 2021
DOI: https://doi.org/10.4143/crt.2021.1019
AbstractAbstract PDFPubReaderePub
Purpose
Salivary gland cancers (SGCs) are relatively rare but comprise various histologic subtypes, which complicates design of prospective trials. Systemic chemotherapy plays a limited role in treatment of SGCs, but cisplatin and docetaxel showed efficacy in a previous preclinical study. Here, we conduct a prospective, phase II study to evaluate the efficacy and toxicities of cisplatin plus weekly docetaxel in patients with metastatic or recurrent SGC.
Materials and Methods
We included patients with histologically confirmed SGCs of the following subtypes: mucoepidermoid carcinoma, adenocarcinoma, ductal carcinoma, or adenoid cystic carcinoma. Patients had no prior systemic chemotherapy for metastatic or recurrent tumors and at least one measurable lesion. Patients were treated with docetaxel 35 mg/m2 (D1, 8) and cisplatin 70 mg/m2 (D1) every 21 days.
Results
Forty-one patients were enrolled between April 2014 and October 2020. The median age was 58 years (range, 32 to 73 years). The most common histologic subtype was adenoid cystic carcinoma (63.4%), followed by ductal carcinoma (24.4%). The most common metastatic site was the lung (75.6%). The median treatment cycle was 5.5 (range, 3 to 8), and the objective response rate was 46.3%, with three complete responses. The median duration of response was 6.8 months (interquartile range, 4.0 to 10.2). The progression-free survival and overall survival were 9.4 months (95% confidence interval [CI], 8.4 to 10.5) and 28.2 months (95% CI, 22.7 to 33.6), respectively. There were no treatment-related deaths. The most common grade 3/4 adverse events were neutropenia (4.9%) and fatigue (4.9%).
Conclusion
Cisplatin plus weekly docetaxel is effective and tolerable with manageable toxicity as first-line therapy in patients with metastatic or recurrent SGC.

Citations

Citations to this article as recorded by  
  • Systemic and Targeted Therapies in Adenoid Cystic Carcinoma
    Alec J. Kacew, Glenn J. Hanna
    Current Treatment Options in Oncology.2023; 24(1): 45.     CrossRef
  • Major and minor salivary gland cancers: A multicenter retrospective study
    Muhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, Efnan Algın, Burcu Gulbagcı, Ilhan Hacibekiroglu, Jamshid Hamdard, Omer Fatih Olmez, Hadi Akkus, Berna Oksuzoglu, Sema Sezgin Goksu, Shute Ailia Dae, Ahmet Taner Sumbul, Muzaffer Ugraklı, Mustafa Ka
    Head & Neck.2023; 45(7): 1643.     CrossRef
  • Prognostic Significance of Primary Tumor Surgery in Adenoid Cystic Carcinoma Patients With Distant Metastases at Diagnosis: A Population-Based Database Analysis in Head and Neck Region
    Han Li, Li Zhao, Yixuan Song, Yang Liu, Song Ni, Shaoyan Liu
    Ear, Nose & Throat Journal.2023;[Epub]     CrossRef
  • The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?
    Robbert Cleymaet, Tijl Vermassen, Renaat Coopman, Hubert Vermeersch, Stijn De Keukeleire, Sylvie Rottey
    International Journal of Molecular Sciences.2022; 23(23): 14891.     CrossRef
  • 6,693 View
  • 187 Download
  • 6 Web of Science
  • 4 Crossref
Close layer
Lung and Thoracic cancer
Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project
Juyoung Kim, Bogeum Cho, Seon-Ha Kim, Chang-Min Choi, Yeol Kim, Min-Woo Jo
Cancer Res Treat. 2022;54(3):728-736.   Published online September 24, 2021
DOI: https://doi.org/10.4143/crt.2021.480
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to evaluate the cost utility of a pilot study of Korean Lung Cancer Screening Project.
Materials and Methods
We constructed a Markov model consisting of 26 states based on the natural history of lung cancer according to the Surveillance, Epidemiology, and End Results summary stage (localized, regional, distant). In the base case, people aged 55-74 years were under consideration for annual screening. Costs and quality-adjusted life years were simulated to calculate the incremental cost utility ratio. Sensitivity analyses were performed on the uncertainty associated with screening target ages, stage distribution, cost, utility, mortality, screening duration, and discount rate.
Results
The base case (US$25,383 per quality-adjusted life year gained) was cost-effective compared to the scenario of no screening and acceptable considering a willingness-to-pay threshold of US$27,000 per quality-adjusted life years gained. In terms of the target age of screening, the age between 60 and 74 years was the most cost-effective. Lung cancer screening was still cost-effective in the sensitivity analyses on the cost for treatment, utility, mortality, screening duration, and less than 5% discount rates, although the result was sensitive to a rise in positive rates or variation of stage distribution.
Conclusion
Our results showed the cost-effectiveness of annual low-dose computed tomography screening for lung cancer in high-risk populations.

Citations

Citations to this article as recorded by  
  • Quantitative risk factor analysis of prior disease condition and socioeconomic status with the multiple myeloma development: nationwide cohort study
    Suein Choi, Eunjin Kim, Jinhee Jung, Sung-Soo Park, Chang-Ki Min, Seunghoon Han
    Scientific Reports.2024;[Epub]     CrossRef
  • Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016
    Sangwon Lee, Eun Hye Park, Bo Yun Jang, Ye Ji Kang, Kyu-Won Jung, Hyo Soung Cha, Kui Son Choi
    Scientific Reports.2024;[Epub]     CrossRef
  • Cost-Effectiveness Analysis of Risk Factor-Based Lung Cancer Screening Program by Low-Dose Computer Tomography in Current Smokers in China
    Tiantian Zhang, Xudong Chen, Caichen Li, Xiaoqin Wen, Tengfei Lin, Jiaxing Huang, Jianxing He, Nanshan Zhong, Jie Jiang, Wenhua Liang
    Cancers.2023; 15(18): 4445.     CrossRef
  • Applying utility values in cost-effectiveness analyses of lung cancer screening: a review of methods
    Preston J. Ngo, Sonya Cressman, Silvia Behar-Harpaz, Deme J. Karikios, Karen Canfell, Marianne F. Weber
    Lung Cancer.2022;[Epub]     CrossRef
  • Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification
    Matthew Fabbro, Kirah Hahn, Olivia Novaes, Mícheál Ó’Grálaigh, James F. O’Mahony
    PharmacoEconomics - Open.2022; 6(6): 773.     CrossRef
  • 6,465 View
  • 217 Download
  • 3 Web of Science
  • 5 Crossref
Close layer
Histologic Changes in Non–Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples
Chang Gok Woo, Seung-Myoung Son, Ho-Chang Lee, Hye Sook Han, Ki Hyeong Lee, Dohun Kim, Eung-Gook Kim, Ok-Jun Lee
Cancer Res Treat. 2022;54(3):737-743.   Published online September 24, 2021
DOI: https://doi.org/10.4143/crt.2021.773
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Histologic change is a resistant mechanism in lung cancer. The most common histological change is the switch from adenocarcinoma (AdenoCa) to small cell carcinoma (SCC) against to tyrosine kinase inhibitors (TKI). However, it is not clear whether other treatment modalities are involved in the histologic changes.
Materials and Methods
We investigated histological changes in eight cases, after various treatments, and compared the molecular profiles between primary tumors and changed tumors using exome sequencing where tissue was available.
Results
Three cases of AdenoCa that were changed into SCC retained the initial mutations after TKI and/or surgical treatment. After treatment with TKI and immunotherapy, an EGFR (epidermal growth factor receptor)-mutant AdenoCa changed to squamous cell carcinoma (SqCa). SqCa in a patient treated with surgery was changed into combined AdenoCa and SqCa. These two cases showed the same genetic variations between the two distinct non–small cell carcinomas (NSCC). Three patients experienced two histologic changes, which the changed tumors returned to its original subtype or changed to a combined tumor after treatments. Four cases showed combined histology in the first or second change.
Conclusion
The histology of NSCC can be changed to a single pattern or combined subtypes after various treatment modalities, and the phenotypic changes seem not fixed. Therefore, additional morphologic changes may occur regardless of their genetic status and types of treatments. To refine the new treatment strategy, consecutive repeated biopsies in progressive disease or recurrent tumor are necessary.

Citations

Citations to this article as recorded by  
  • Using ex vivo bioengineered lungs to model pathologies and screening therapeutics: A proof‐of‐concept study
    Mohammadali Ahmadipour, Jorge Castilo Prado, Benyamin Hakak‐Zargar, Malik Quasir Mahmood, Ian M. Rogers
    Biotechnology and Bioengineering.2024; 121(10): 3020.     CrossRef
  • Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
    Shuo Li, Wenyuan Li, Bin Liu, Kostyantyn Krysan, Steven M. Dubinett
    Cancer Research Communications.2024; 4(7): 1738.     CrossRef
  • Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases
    Alessandro Bonis, Andrea Dell’Amore, Vincenzo Verzeletti, Luca Melan, Giovanni Zambello, Chiara Nardocci, Giovanni Maria Comacchio, Federica Pezzuto, Fiorella Calabrese, Federico Rea
    Journal of Clinical Medicine.2023; 12(4): 1411.     CrossRef
  • Gene‐level dissection of chromosome 3q locus amplification in squamous cell carcinoma of the lung using the nCounter assay
    Taesung Jeon, Uk Jeen Oh, Jaeyoung Min, Chungyeul Kim
    Thoracic Cancer.2023; 14(26): 2635.     CrossRef
  • Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience
    Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Young Seob Shin, Sei Won Lee, Wonjun Ji, Chang-Min Choi, Eun Kyung Choi
    Cancer Research and Treatment.2023; 55(4): 1181.     CrossRef
  • Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler
    Sharia Hernandez, Rossana Lazcano, Alejandra Serrano, Steven Powell, Larissa Kostousov, Jay Mehta, Khaja Khan, Wei Lu, Luisa M. Solis
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 6,322 View
  • 208 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Predictive Value of Interstitial Lung Abnormalities for Postoperative Pulmonary Complications in Elderly Patients with Early-stage Lung Cancer
Won Gi Jeong, Yun-Hyeon Kim, Jong Eun Lee, In-Jae Oh, Sang Yun Song, Kum Ju Chae, Hye Mi Park
Cancer Res Treat. 2022;54(3):744-752.   Published online September 28, 2021
DOI: https://doi.org/10.4143/crt.2021.772
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Identifying pretreatment interstitial lung abnormalities (ILAs) is important because of their predictive value for complications after lung cancer treatment. This study aimed to assess the predictive value of ILAs for postoperative pulmonary complications (PPCs) in elderly patients undergoing curative resection for early-stage non-small cell lung cancer (NSCLC).
Materials and Methods
Elderly patients (age ≥ 70 years) who underwent curative resection for pathologic stage I or II NSCLC with normal preoperative spirometry results (pre-bronchodilator forced expiratory volume in 1 s to forced vital capacity [FVC] ratio > 0.70 and FVC ≥ 80% of the predicted value) between January 2012 and December 2019 were retrospectively identified. Univariable and multivariable regression analyses were performed to assess risk factors for PPCs. The Kaplan–Meier method and log-rank test were used to analyze the relationship between ILAs and postoperative mortality. One-way analysis of variance was performed to assess the correlation between ILAs and hospital stay duration.
Results
A total of 262 patients (median age, 73 [interquartile range, 71–76] years; 132 male) were evaluated. A multivariable logistic regression model revealed that, among several relevant risk factors, fibrotic ILAs independently predicted both overall PPCs (adjusted odds ratio [OR], 4.84; 95% confidence interval [CI], 1.35–17.38; p=0.016) and major PPCs (adjusted OR, 8.72; 95% CI, 1.71–44.38; p=0.009). Fibrotic ILAs were significantly associated with higher postoperative mortality and longer hospital stay (F=5.21, p=0.006).
Conclusion
Pretreatment fibrotic ILAs are associated with PPCs, higher postoperative mortality, and longer hospital stay.

Citations

Citations to this article as recorded by  
  • Pretreatment Interstitial Lung Abnormalities Detected on Abdominal Computed Tomography Scans in Prostate Cancer Patients
    Hyun Jin Kim, Won Gi Jeong, Jeong Yeop Lee, Hyo-Jae Lee, Byung Chan Lee, Hyo Soon Lim, Yun-Hyeon Kim
    Journal of Computer Assisted Tomography.2024; 48(3): 406.     CrossRef
  • Interstitial Lung Abnormalities
    Noriaki Wada, Gary M. Hunninghake, Hiroto Hatabu
    Clinics in Chest Medicine.2024; 45(2): 433.     CrossRef
  • Incidence and risk factors of pulmonary complications after lung cancer surgery: A systematic review and meta-analysis
    Ting Deng, Jiamei Song, Jinmei Tuo, Yu Wang, Jin Li, Lorna Kwai Ping Suen, Yan Liang, Junliang Ma, Shaolin Chen
    Heliyon.2024; 10(12): e32821.     CrossRef
  • Survival impact of fibrotic interstitial lung abnormalities in resected stage IA non-small cell lung cancer
    Won Gi Jeong, Yun-Hyeon Kim
    The British Journal of Radiology.2023;[Epub]     CrossRef
  • Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer
    Yoon Joo Shin, Jeong Geun Yi, Mi Young Kim, Donghee Son, Su Yeon Ahn
    Journal of Clinical Medicine.2023; 12(21): 6858.     CrossRef
  • Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
    Pengfei Wang, Li Zhang, Qian Guo, Lifen Zhao, Yanyan Hao
    Open Medicine.2023;[Epub]     CrossRef
  • Clinical implication of interstitial lung abnormality in elderly patients with early‐stage non‐small cell lung cancer
    Seong Woo Cho, Won Gi Jeong, Jong Eun Lee, In‐Jae Oh, Sang Yun Song, Hye Mi Park, Hyo‐Jae Lee, Yun‐Hyeon Kim
    Thoracic Cancer.2022; 13(7): 977.     CrossRef
  • 6,634 View
  • 165 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer
Yu Feng, Yutao Liu, Mingming Yuan, Guilan Dong, Hongxia Zhang, Tongmei Zhang, Lianpeng Chang, Xuefeng Xia, Lifeng Li, Haohua Zhu, Puyuan Xing, Hongyu Wang, Yuankai Shi, Zhijie Wang, Xingsheng Hu
Cancer Res Treat. 2022;54(3):753-766.   Published online October 5, 2021
DOI: https://doi.org/10.4143/crt.2021.905
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
To investigate the feasibility of biomarkers based on dynamic circulating tumor DNA (ctDNA) to classify small cell lung cancer (SCLC) into different subtypes.
Materials and Methods
Tumor and longitudinal plasma ctDNA samples were analyzed by next-generation sequencing of 1,021 genes. PyClone was used to infer the molecular tumor burden index (mTBI). Pre-treatment tumor tissues [T1] and serial plasma samples were collected (pre-treatment [B1], after two [B2], six [B3] cycles of chemotherapy and at progression [B4]).
Results
Overall concordance between T1 and B1 sequencing (n=30) was 66.5%, and 89.5% in the gene of RB1. A classification method was designed according to the changes of RB1 mutation, named as subtype Ⅰ (both positive at B1 and B2), subtype Ⅱ (positive at B1 but negative at B2), and subtype Ⅲ (both negative at B1 and B2). The median progressive-free survival for subtype Ⅰ patients (4.5 months [95%CI: 2.6-5.8]) was inferior to subtype Ⅱ (not reached, p<0.0001) and subtype Ⅲ (10.8 months [95%CI: 6.0-14.4], p=0.002). The median overall survival for subtype Ⅰ patients (16.3 months [95%CI: 5.3-22.9]) was inferior to subtype Ⅱ (not reached, p=0.01) and subtype Ⅲ (not reached, p=0.02). Patients with a mTBI dropped to zero at B2 had longer median overall survival (not reached vs. 19.5 months, p=0.01). The changes of mTBI from B4 to B1 were sensitive to predict new metastases, with a sensitivity of 100% and a specificity of 85.7%.
Conclusion
Monitoring ctDNA based RB1 mutation and mTBI provided a feasible tool to predict the prognosis of SCLC.

Citations

Citations to this article as recorded by  
  • Cell-free and extrachromosomal DNA profiling of small cell lung cancer
    Roya Behrouzi, Alexandra Clipson, Kathryn L. Simpson, Fiona Blackhall, Dominic G. Rothwell, Caroline Dive, Florent Mouliere
    Trends in Molecular Medicine.2024;[Epub]     CrossRef
  • Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration
    Changshu Li, Jun Shao, Peiyi Li, Jiaming Feng, Jingwei Li, Chengdi Wang
    Cancer Letters.2023; 577: 216365.     CrossRef
  • Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients
    Fan Yang, Min Tang, Liang Cui, Jing Bai, Jiangyong Yu, Jiayi Gao, Xin Nie, Xu Li, Xuefeng Xia, Xin Yi, Ping Zhang, Lin Li
    Thoracic Cancer.2023; 14(31): 3097.     CrossRef
  • Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
    Ugo Testa, Elvira Pelosi, Germana Castelli
    Onco.2022; 2(3): 186.     CrossRef
  • 6,479 View
  • 197 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer
Shinkyo Yoon, Hannah Yang, Hyun-Min Ryu, Eunjin Lee, Yujin Jo, Seyoung Seo, Deokhoon Kim, Chang Hoon Lee, Wanlim Kim, Kyung Hae Jung, Sook Ryun Park, Eun Kyung Choi, Sang-We Kim, Kang-Seo Park, Dae Ho Lee
Cancer Res Treat. 2022;54(3):767-781.   Published online September 30, 2021
DOI: https://doi.org/10.4143/crt.2021.651
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Heat shock protein-90 (HSP90) remains an important cancer target because of its involvement in multiple oncogenic protein pathways and biologic processes. Although many HSP90 inhibitors have been tested in the treatment of KRAS-mutant non–small cell lung cancer (NSCLC), most, including AUY922, have failed due to toxic effects and resistance generation, even though a modest efficacy has been observed for these drugs in clinical trials. In our present study, we investigated the novel mechanism of resistance to AUY922 to explore possible avenues of overcoming and want to provide some insights that may assist with the future development of successful next-generation HSP90 inhibitors.
Materials and Methods
We established two AUY922-resistant KRAS-mutated NSCLC cells and conducted RNA sequencing to identify novel resistance biomarker.
Results
We identified novel two resistance biomarkers. We observed that both integrin Av (ITGAv) and β3 (ITGB3) induce AUY922-resistance via focal adhesion kinase (FAK) activation, as well as an epithelial-mesenchymal transition, in both in vitro and in vivo xenograft model. mRNAs of both ITGAv and ITGB3 were also found to be elevated in a patient who had shown acquired resistance in a clinical trial of AUY922. ITGAv was induced by miR-142 downregulation, and ITGB3 was increased by miR-150 downregulation during the development of AUY922-resistance. Therefore, miR-150 and miR-142 overexpression effectively inhibited ITGAvB3-dependent FAK activation, restoring sensitivity to AUY922.
Conclusion
The synergistic co-targeting of FAK and HSP90 attenuated the growth of ITGAvB3-induced AUY922-resistant KRAS-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome acquired AUY922-resistance in KRAS-mutant NSCLC.

Citations

Citations to this article as recorded by  
  • Integrin αV Inhibition by GMI, a Ganoderma Microsporum Immunomodulatory Protein, Abolish Stemness and Migration in EGFR‐Mutated Lung Cancer Cells Resistant to Osimertinib
    Yu‐Ting Kang, Hui‐Yi Chang, Ya‐Chu Hsieh, Chia‐Hsuan Chou, I‐Lun Hsin, Jiunn‐Liang Ko
    Environmental Toxicology.2024;[Epub]     CrossRef
  • Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway
    Kaitao Zhu, Shiwei Li, Hongru Yao, Jilong Hei, WenGuo Jiang, Tracey Martin, Shanyi Zhang
    Journal of Neuro-Oncology.2024;[Epub]     CrossRef
  • Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence
    Bashar Alhasan, Marina Mikeladze, Irina Guzhova, Boris Margulis
    Cancer and Metastasis Reviews.2023; 42(1): 217.     CrossRef
  • 8,477 View
  • 269 Download
  • 2 Web of Science
  • 3 Crossref
Close layer
Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma
Inwoo Hwang, Yoon-La Choi, Hyunwoo Lee, Soohyun Hwang, Boram Lee, Hobin Yang, Chaithanya Chelakkot, Joungho Han
Cancer Res Treat. 2022;54(3):782-792.   Published online November 23, 2021
DOI: https://doi.org/10.4143/crt.2021.843
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The incidence of BRAF V600E mutation in non-small cell lung carcinoma (NSCLC) is lower than 2%, which poses difficulties in finding legitimate patients for targeted therapy. We investigated the predictive factors pertaining to BRAF V600E and the effectiveness of the VE1 antibody as a screening method for patient selection.
Materials and Methods
The study was designed into two steps. In a first group, BRAF-mutated NSCLCs were identified from sequencing data to determine the features of BRAF V600E mutation. The results of the first group helped the collection of adenocarcinomas with a papillary or micropapillary pattern but without EGFR or ALK alterations as a second group so that the frequency of BRAF V600E mutation could be calculated. The sensitivity and specificity of the VE1 were compared with BRAF V600E status.
Results
Among 39 BRAF-mutated NSCLCs in the first group, 20 (51%) were V600E. BRAF V600E mutation was more common in female patients and showed no significant correlation with smoking status. Nineteen cases were adenocarcinomas without EGFR and ALK alterations. The most common patterns of invasion were papillary and micropapillary along with central fibrosis. The sensitivity and specificity of the VE1 were 90.0% and 92.3%, respectively. In the second group, 6.7% of cases were VE1-positive, indicating that the prevalence was significantly higher than that reported in previous studies (0.3-1.8%).
Conclusion
BRAF V600E-mutated NSCLCs could be enriched with the application of clinicopathologic parameters, which are not perfect. Therefore, additional VE1 immunohistochemistry may be useful as a screening method.

Citations

Citations to this article as recorded by  
  • The rapidly changing field of predictive biomarkers of non-small cell lung cancer
    László József Tóth, Attila Mokánszki, Gábor Méhes
    Pathology and Oncology Research.2024;[Epub]     CrossRef
  • BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
    Hyo Yeong Ahn, Chang Hun Lee, Min Ki Lee, Jung Seop Eom, Yeon Joo Jeong, Yeong Dae Kim, Jeong Su Cho, Jonggeun Lee, So Jeong Lee, Dong Hoon Shin, Ahrong Kim
    Medicina.2023; 59(6): 1085.     CrossRef
  • The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients
    Jonnathan Roldan Ruiz, Marta Fuentes Gago, Luis Chinchilla Tabora, Idalia Gonzalez Morais, José Sayagués, Mar Abad Hernández, Maria Cordovilla Pérez, Maria Ludeña de la Cruz, Edel del Barco Morillo, Marta Rodriguez Gonzalez
    Diagnostics.2023; 13(14): 2347.     CrossRef
  • Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
    Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha
    Journal of Pathology and Translational Medicine.2022; 56(6): 334.     CrossRef
  • 6,226 View
  • 167 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Usefulness of Pulmonary Rehabilitation in Non-Small Cell Lung Cancer Patients Based on Pulmonary Function Tests and Muscle Analysis Using Computed Tomography Images
Juwhan Choi, Zepa Yang, Jinhwan Lee, Jun Hee Lee, Hyun Koo Kim, Hwan Seok Yong, Sung Yong Lee
Cancer Res Treat. 2022;54(3):793-802.   Published online October 20, 2021
DOI: https://doi.org/10.4143/crt.2021.769
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The usefulness of rehabilitation in patients with reduced lung function before lung surgery remains unclear, and there is no adequate method for evaluating the effect of rehabilitation. We aimed to evaluate the usefulness of rehabilitation in patients with non-small cell lung cancer (NSCLC) undergoing lung cancer surgery.
Materials and Methods
We retrospectively analyzed the medical records of NSCLC patients at Korea University Guro Hospital between 2018 and 2020. Patients were divided into two groups depending on whether they underwent rehabilitation. Pulmonary function test (PFT) data and muscle determined using chest computed tomography (CT) images were analyzed. Because the baseline characteristics were different between the two groups, propensity score matching was performed.
Results
Of 325 patients, 75 (23.1%) and 250 (76.9%) were included in the rehabilitation and non-rehabilitation (control) groups, respectively. The rehabilitation group had a worse general condition at baseline. After propensity score matching, 45 patients remained in each group. Pulmonary function (forced expiratory volume in 1 second, %) (p=0.001) and the Hounsfield unit of erector spinae muscle (p=0.001) were better preserved in the rehabilitation group. Muscle loss of 3.4% and 0.6% was observed in the control and rehabilitation groups, respectively (p=0.003). In addition, the incidence of embolic events was lower in the rehabilitation group (p=0.044).
Conclusion
Pulmonary rehabilitation is useful in patients with NSCLC undergoing lung surgery. Pulmonary rehabilitation preserves lung function, muscle and reduces embolic events after surgery. Pulmonary rehabilitation is recommended for patients with NSCLC undergoing surgery.

Citations

Citations to this article as recorded by  
  • Impact of pulmonary rehabilitation on exercise capacity, health-related quality of life, and cardiopulmonary function in lung surgery patients: a retrospective propensity score-matched analysis
    Chunlai Niu, Huan Lin, Zinan Zhang, Qing Wang, Yingjun Wei
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Trial
    Mi Mi Ko, Mi-Kyung Jeong, Chang Min Choi, Seung Hyeun Lee, Jaemoo Chun, Jin-Mu Yi, Ho Jang, Sung Yong Lee
    International Journal of Environmental Research and Public Health.2023; 20(5): 4507.     CrossRef
  • Association of Preoperative Rehabilitation With Postoperative Length of Hospital Stay for Elderly Lung Cancer Patients
    Kohei FUNATSU, Ryutaro MATSUGAKI, Hanaka IMAMURA, Masaru TAKENAKA, Fumihiro TANAKA, Kiyohide FUSHIMI, Shinya MATSUDA, Satoru SAEKI
    Journal of UOEH.2023; 45(3): 155.     CrossRef
  • Comprehensive pulmonary rehabilitation for a 90-year-old patient with intertrochanteric fracture complicated by chronic obstructive pulmonary disease: a case report
    Hui Teng, Jun Tian, Qing Shu
    Physiotherapy Theory and Practice.2023; : 1.     CrossRef
  • Research Status and Progress of Lung Rehabilitation after Lung Cancer Operation
    莉 袁
    Advances in Clinical Medicine.2023; 13(09): 14955.     CrossRef
  • Rapid Recovery of Postoperative Pulmonary Function in Patients With Lung Cancer and Influencing Factors
    Yang Fuzhi, Tang Dongfang, Fu Wentao, Wang Jing, Wu Yingting, Mo Nianping, Gao Wen, Shen Xiaoyong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Bilan fonctionnel préopératoire du cancer bronchique
    J. Frija-Masson
    Revue des Maladies Respiratoires Actualités.2022; 14(2): 2S75.     CrossRef
  • 6,261 View
  • 162 Download
  • 4 Web of Science
  • 7 Crossref
Close layer
Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials
Qing Yin, Longguo Dai, Ruizhu Sun, Ping Ke, Liya Liu, Bo Jiang
Cancer Res Treat. 2022;54(3):803-816.   Published online October 25, 2021
DOI: https://doi.org/10.4143/crt.2021.764
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This network meta-analysis (NMA) was conducted to compare the efficacy of immune checkpoint inhibitors in advanced non–small cell lung cancer (NSCLC) patients with liver metastases.
Materials and Methods
English literature was retrieved from the PubMed, American Society of Clinical Oncology, and European Society for Medical Oncology databases from January 2015 to January 2021. We pooled the overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) using an NMA and ranked treatments by the surface under the cumulative ranking curve. Publication bias was evaluated by Begg’s and Egger’s tests. STATA 15.0 was used for the sensitivity analysis, and the remaining statistical analyses were performed using R 4.0.2.
Results
Nine eligible phase III randomized controlled trials were included, including 1,141 patients with liver metastases. Pembrolizumab+chemotherapy ranked highest, followed by atezolizumab+bevacizumab+chemotherapy and nivolumab. However, no significant difference in OS rates was observed across these three treatments (HR, 0.98; 95% confidence interval [CI], 0.43 to 2.22 for pembrolizumab+chemotherapy vs. atezolizumab+bevacizumab+chemotherapy; HR, 0.91; 95% CI, 0.52 to 1.57 for pembrolizumab+chemotherapy vs. nivolumab). Regarding the PFS rate, atezolizumab+bevacizumab+chemotherapy and pembro-lizumab+chemotherapy ranked highest and no significant difference was observed between them (HR, 0.79; 95% CI, 0.36 to 1.70 for atezolizumab+bevacizumab+chemotherapy vs. pembrolizumab+chemotherapy).
Conclusion
Pembrolizumab+chemotherapy, atezolizumab+bevacizumab+chemotherapy, and nivolumab were superior to other treatments in NSCLC patients with liver metastases. These new findings may help clinicians better select therapeutic strategies for NSCLC patients with liver metastases.

Citations

Citations to this article as recorded by  
  • Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases
    Fan-jie Qu, Yi Zhou, Shuang Wu
    British Journal of Cancer.2024; 130(2): 165.     CrossRef
  • Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
    Daisuke Hazama, Kenji Nakahama, Hiroaki Kodama, Akito Miyazaki, Koichi Azuma, Yosuke Kawashima, Yuki Sato, Kentaro Ito, Yoshimasa Shiraishi, Keita Miura, Takayuki Takahama, Satoshi Oizumi, Yoshinobu Namba, Satoshi Ikeda, Hiroshige Yoshioka, Asuka Tsuya, Y
    JTO Clinical and Research Reports.2024; 5(1): 100613.     CrossRef
  • Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer
    Lingling Zhu, Xianzhe Yu, Xiaojun Tang, Chenggong Hu, Lei Wu, Yanyang Liu, Qinghua Zhou
    Chinese Medical Journal.2024; 137(9): 1019.     CrossRef
  • Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis
    Huilin Xu, Pingpo Ming, Zhenyu Zhao, Nan Zhao, Dingjie Zhou, Xixian Tang, Dedong Cao
    Integrative Cancer Therapies.2023;[Epub]     CrossRef
  • Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
    Handai Xia, Wengang Zhang, Yuqing Zhang, Xiaoling Shang, Yanguo Liu, Xiuwen Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 7,521 View
  • 252 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer
Noeul Kang, Ki Hwan Kim, Byeong-Ho Jeong, Kyungjong Lee, Hojoong Kim, O Jung Kwon, Myung-Ju Ahn, Jeonghee Cho, Ho Yun Lee, Sang-Won Um
Cancer Res Treat. 2022;54(3):817-826.   Published online November 9, 2021
DOI: https://doi.org/10.4143/crt.2021.822
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The role of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) in the management of persistent subsolid nodules (SSNs) is unclear. This study aimed to investigate the impact of EGFR-TKIs on concurrent SSNs in patients with stage IV non–small cell lung cancer (NSCLC).
Materials and Methods
Patients who received an EGFR-TKI for at least 1 month for stage IV NSCLC and had concurrent SSN(s) that had existed for at least 3 months on chest computed tomography were included in this retrospective study. Size change of each nodule before and after EGFR-TKI therapies were evaluated using a cutoff value of 2 mm; increase (≥ 2 mm), decrease (≤ –2 mm), and no change (–2 mm < size change < +2 mm).
Results
A total of 77 SSNs, 51 pure ground-glass (66.2%) and 26 part-solid nodules (33.8%), were identified in 59 patients who received gefitinib (n=45) and erlotinib (n=14). Among 58 EGFR mutation analysis performed for primary lung cancer, 45 (77.6%) were EGFR mutant. The proportions of decrease group were 19.5% (15/77) on per-nodule basis and 25.4% (15/59) on per-patient basis. Four SSNs (5.2%) disappeared completely. On per-patient based multivariable analysis, EGFR exon 19 deletion positivity for primary lung cancer was associated with a decrease after initial EGFR-TKI therapy (adjusted odds ratio, 4.29; 95% confidence interval, 1.21 to 15.29; p=0.025).
Conclusion
Approximately 20% of the concurrent SSNs decreased after the initial EGFR-TKI therapy. EGFR exon 19 deletion positivity for primary lung cancer was significantly associated with the size change of concurrent SSNs.

Citations

Citations to this article as recorded by  
  • Genetic Polymorphisms of ACE1 Rs4646994 Associated with Lung Cancer in Patients with Pulmonary Nodules: A Case–Control Study
    Rong Qiao, Siyao Sang, Jiajun Teng, Hua Zhong, Hui Li, Baohui Han
    Biomedicines.2023; 11(6): 1549.     CrossRef
  • Deep learning analysis to predict EGFR mutation status in lung adenocarcinoma manifesting as pure ground-glass opacity nodules on CT
    Hyun Jung Yoon, Jieun Choi, Eunjin Kim, Sang-Won Um, Noeul Kang, Wook Kim, Geena Kim, Hyunjin Park, Ho Yun Lee
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 6,231 View
  • 163 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Breast cancer
Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
Yoon Ju Bang, Won Kyung Kwon, Seok Jin Nam, Seok Won Kim, Byung-Joo Chae, Se Kyung Lee, Jai Min Ryu, Jong-Won Kim, Jonghan Yu, Jeong Eon Lee
Cancer Res Treat. 2022;54(3):827-833.   Published online October 13, 2021
DOI: https://doi.org/10.4143/crt.2021.791
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant.
Materials and Methods
This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants (PVs/LPVs) were reviewed.
Results
A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer (TNBC) and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All 7 cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected.
Conclusion
We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1.

Citations

Citations to this article as recorded by  
  • Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
    Junjie Pan, Ning Ren, Lanqi Ren, YiBei Yang, Qiaoping Xu
    Scientific Reports.2024;[Epub]     CrossRef
  • Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants
    Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang, Yuntao Xie
    Breast Cancer Research and Treatment.2024; 208(1): 155.     CrossRef
  • Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
    Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim
    Cancer Genetics.2022; 266-267: 19.     CrossRef
  • 6,128 View
  • 244 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors
Sungkeun Shim, Danbee Kang, Nayeon Kim, Gayeon Han, Jihyun Lim, Hyunsoo Kim, Jeonghyun Park, Mankyung Lee, Jeong Eon Lee, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Jai Min Ryu, Seok Jin Nam, Se Kyung Lee, Juhee Cho
Cancer Res Treat. 2022;54(3):834-841.   Published online October 13, 2021
DOI: https://doi.org/10.4143/crt.2021.784
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COmprehensive Score for financial Toxicity in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors.
Materials and Methods
We conducted linguistic validation following a standardized methodology recommended by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans). For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques.
Results
The COST-K demonstrated good internal consistency, with a Cronbach’s α of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r=–0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting, –0.18; constipation, –0.14; diarrhea, –0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0 to 44; mean±standard deivation [SD], 27.1±7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity.
Conclusion
The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the health-related quality of life, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions.

Citations

Citations to this article as recorded by  
  • Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy
    Jeremy P. Harris, Eric Ku, Garrett Harada, Sophie Hsu, Elaine Chiao, Pranathi Rao, Erin Healy, Misako Nagasaka, Jessica Humphreys, Michael A. Hoyt
    American Journal of Hospice and Palliative Medicine®.2024; 41(6): 592.     CrossRef
  • Financial Toxicity in Radiation Oncology: Impact for Our Patients and for Practicing Radiation Oncologists
    Victoria S. Wu, Xinglei Shen, Janet de Moor, Fumiko Chino, Jonathan Klein
    Advances in Radiation Oncology.2024; 9(3): 101419.     CrossRef
  • Measures of financial toxicity in cancer survivors: a systematic review
    L. B. Thomy, M. Crichton, L. Jones, P. M. Yates, N. H. Hart, L. G. Collins, R. J. Chan
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Validation of the COmprehensive Score for Financial Toxicity (COST) in Vietnamese patients with cancer
    Binh Thang Tran, Dinh Duong Le, Thanh Gia Nguyen, Minh Tu Nguyen, Minh Hanh Nguyen, Cao Khoa Dang, Dinh Trung Tran, Le An Pham
    PLOS ONE.2024; 19(6): e0306339.     CrossRef
  • Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis
    Stevanus Pangestu, Fanni Rencz
    Value in Health.2023; 26(2): 300.     CrossRef
  • Association between financial toxicity and health-related quality of life of patients with gynecologic cancer
    Yusuke Kajimoto, Kazunori Honda, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takashi Shibutani, Shoji Nagao, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Keiichi Fujiwara, Ataru Igarashi
    International Journal of Clinical Oncology.2023; 28(3): 454.     CrossRef
  • Financial Toxicity Following Cancer in a Middle-Income Country with a Pluralistic Health System: Validation of the COST Questionnaire
    Veni V. Sakti, Mahmoud Danaee, Cheng-Har Yip, Ros S. A. Bustamam, Marniza Saad, Gin Gin Gan, Jerome Tan, Yueh Ni Lim, Flora L.T. Chong, Murallitharan Munisamy, Farahida Mohd Farid, Boon Lui Sew, Yek-Ching Kong, Nishalini Muniandy, Nirmala Bhoo-Pathy
    Cancer Care Research Online.2023; 3(3): e044.     CrossRef
  • Financial Toxicity Among Breast Cancer Patients
    Yi Kuang, Xiaoyi Yuan, Zheng Zhu, Weijie Xing
    Cancer Nursing.2023;[Epub]     CrossRef
  • Heterogeneity of financial toxicity and associated risk factors for older cancer survivors in China
    Mingzhu Su, Siqi Liu, Li Liu, Fang Wang, Jiahui Lao, Xiaojie Sun
    iScience.2023; 26(10): 107768.     CrossRef
  • Evaluation of financial toxicity and associated factors in female patients with breast cancer: a systematic review and meta-analysis
    Yusuf Çeli̇k, Sevilay Şenol Çeli̇k, Seda Sarıköse, Hande Nur Arslan
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer
    Yusuke Kajimoto, Takashi Shibutani, Shoji Nagao, Satoshi Yamaguchi, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Kazunori Honda, Ataru Igarashi
    International Journal of Gynecologic Cancer.2022; : ijgc-2022-003410.     CrossRef
  • 6,941 View
  • 180 Download
  • 9 Web of Science
  • 11 Crossref
Close layer
Gastrointestinal cancer
Trends in the Performance of the Korean National Cancer Screening Program for Gastric Cancer from 2007 to 2016
Ji Eun Ryu, Eunji Choi, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu Won Jung, Kui Son Choi
Cancer Res Treat. 2022;54(3):842-849.   Published online September 30, 2021
DOI: https://doi.org/10.4143/crt.2021.482
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The Korean National Cancer Screening Program (KNCSP) has implemented two screening methods for gastric cancer—upper gastrointestinal series (UGIS) and endoscopy—for Koreans aged ≥40 years. We aimed to assess performance trends for both screening methods.
Materials and Methods
The KNCSP database was used to evaluate individuals who underwent screening from 2007 to 2016. The final gastric cancer diagnosis was ascertained by linking with the Korean Central Cancer Registry. We conducted a prospective, cross-sectional analysis to estimate performance indicators of gastric cancer screening by UGIS and endoscopy, stratified by sociodemographic factors.
Results
We found that screening rates for gastric cancer increased from 28% to 51.7% between 2007 and 2016, and that the rate of endoscopy use for gastric cancer screening increased sharply. Cancer detection rates (CDR) of UGIS and endoscopy were 0.41 and 2.25 per 1,000 screens in 2007–2008 and 0.26 and 1.99 in 2015–2016, respectively. Interval cancer rates (ICR) per 1,000 negative screenings were 1.33 (2007–2008) and 1.21 (2015–2016) for UGIS and 1.14 (2007–2008) and 0.88 (2015–2016) for endoscopy. The sensitivity of UGIS decreased from 23.6% (2007–2008) to 17.6% (2015–2016), whereas that of endoscopy increased from 66.4% (2007–2008) to 69.3% (2015–2016). Specificity was maintained at >99% for both methods over the study period.
Conclusion
The use of endoscopy for gastric cancer screening within the KNCSP has increased. Endoscopy has higher CDR, sensitivity, and specificity, and lower ICR estimates than does UGIS.

Citations

Citations to this article as recorded by  
  • Barriers to upper gastrointestinal screening among the general population in high-prevalence areas: a cross-sectional study
    Xin Chen, Yuan Ze, Wanya Yi, Yuling Yang, Renjuan Sun, Huiming Tu
    JBI Evidence Implementation.2024; 22(2): 218.     CrossRef
  • Carbon footprint and cost reduction by endoscopic grading of gastric intestinal metaplasia using narrow‐band imaging
    Jun‐Hyung Cho, So‐Young Jin, Suyeon Park
    Journal of Gastroenterology and Hepatology.2024; 39(5): 942.     CrossRef
  • Family history and gastric cancer incidence and mortality in Asia: a pooled analysis of more than half a million participants
    Dan Huang, Minkyo Song, Sarah Krull Abe, Md. Shafiur Rahman, Md. Rashedul Islam, Eiko Saito, Katherine De la Torre, Norie Sawada, Akiko Tamakoshi, Xiao-Ou Shu, Hui Cai, Atsushi Hozawa, Seiki Kanemura, Jeongseon Kim, Yu Chen, Hidemi Ito, Yumi Sugawara, Sue
    Gastric Cancer.2024; 27(4): 701.     CrossRef
  • Efficacy and safety of three-dimensional magnetically assisted capsule endoscopy for upper gastrointestinal and small bowel examination
    Dong Jun Oh, Yea Je Lee, Sang Hoon Kim, Joowon Chung, Hyun Seok Lee, Ji Hyung Nam, Yun Jeong Lim, Thomas Lui Ka Luen
    PLOS ONE.2024; 19(5): e0295774.     CrossRef
  • A mathematical simulation model to determine the optimal endoscopic screening strategy for detection of H. pylori-naïve gastric neoplasms
    Fumiaki Ishibashi, Kosuke Okusa, Yoshitaka Tokai, Toshiaki Hirasawa, Tomohiro Kawakami, Kentaro Mochida, Yuka Yanai, Chizu Yokoi, Yuko Hayashi, Shun-ichiro Ozawa, Koji Uraushihara, Yohei Minato, Hiroyuki Nakanishi, Hiroya Ueyama, Mikinori Kataoka, Yuzo To
    Gastric Cancer.2024; 27(5): 1078.     CrossRef
  • Association between gastrectomy and the risk of type 2 diabetes in gastric cancer survivors: A nationwide cohort study
    Gyuri Kim, Kyung-do Han, So Hyun Cho, Rosa Oh, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
    Diabetes & Metabolism.2024; 50(5): 101569.     CrossRef
  • Estimating Age-Specific Mean Sojourn Time of Breast Cancer and Sensitivity of Mammographic Screening by Breast Density among Korean Women
    Eunji Choi, Mina Suh, So-Youn Jung, Kyu-Won Jung, Sohee Park, Jae Kwan Jun, Kui Son Choi
    Cancer Research and Treatment.2023; 55(1): 136.     CrossRef
  • Early Gastric Cancer: Update on Prevention, Diagnosis and Treatment
    Clara Benedetta Conti, Stefano Agnesi, Miki Scaravaglio, Pietro Masseria, Marco Emilio Dinelli, Massimo Oldani, Fabio Uggeri
    International Journal of Environmental Research and Public Health.2023; 20(3): 2149.     CrossRef
  • Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
    Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
    Journal of Gastric Cancer.2023; 23(1): 3.     CrossRef
  • Risk of upper gastrointestinal cancer and death in persons with negative screening results: results from the National Cancer Screening Program in South Korea
    Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Il Ju Choi, Kui Son Choi
    Gastric Cancer.2023; 26(4): 580.     CrossRef
  • Descriptive Analysis of Gastric Cancer Mortality in Korea, 2000-2020
    Tung Hoang, Hyeongtaek Woo, Sooyoung Cho, Jeeyoo Lee, Sayada Zartasha Kazmi, Aesun Shin
    Cancer Research and Treatment.2023; 55(2): 603.     CrossRef
  • Helicobacter pylori infection
    Peter Malfertheiner, M. Constanza Camargo, Emad El-Omar, Jyh-Ming Liou, Richard Peek, Christian Schulz, Stella I. Smith, Sebastian Suerbaum
    Nature Reviews Disease Primers.2023;[Epub]     CrossRef
  • A 6-year nationwide population-based study on the current status of gastric endoscopic resection in Korea using administrative data
    Jae Yong Park, Mi-Sook Kim, Beom Jin Kim, Jae Gyu Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • How to Improve the Efficacy of Gastric Cancer Screening?
    Wladyslaw Januszewicz, Maryla Helena Turkot, Jaroslaw Regula
    Current Treatment Options in Gastroenterology.2023; 21(3): 241.     CrossRef
  • Effect of gastric cancer screening on long-term survival of gastric cancer patients: results of Korean national cancer screening program
    Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Kui Son Choi
    Journal of Gastroenterology.2022; 57(7): 464.     CrossRef
  • Endoscopic Treatment of Superficial Gastric Cancer: Present Status and Future
    Hiroyuki Hisada, Yoshiki Sakaguchi, Kaori Oshio, Satoru Mizutani, Hideki Nakagawa, Junichi Sato, Dai Kubota, Miho Obata, Rina Cho, Sayaka Nagao, Yuko Miura, Hiroya Mizutani, Daisuke Ohki, Seiichi Yakabi, Yu Takahashi, Naomi Kakushima, Yosuke Tsuji, Nobuta
    Current Oncology.2022; 29(7): 4678.     CrossRef
  • Impact of the COVID-19 Pandemic on Gastric Cancer Screening in South Korea: Results From the Korean National Cancer Screening Survey (2017–2021)
    Kyeongmin Lee, Mina Suh, Jae Kwan Jun, Kui Son Choi
    Journal of Gastric Cancer.2022; 22(4): 297.     CrossRef
  • Status of Endoscopic Screening Strategies for Upper Gastrointestinal Tract Cancer
    Bin Lyu, Xiao-Liang Jin
    Cancer Screening and Prevention.2022; 000(000): 000.     CrossRef
  • 7,741 View
  • 218 Download
  • 19 Web of Science
  • 18 Crossref
Close layer
Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases
Jesang Yu, Dong Hwan Kim, Jungbok Lee, Yong Moon Shin, Jong Hoon Kim, Sang Min Yoon, Jinhong Jung, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Jin-hong Park, So Yeon Kim
Cancer Res Treat. 2022;54(3):850-859.   Published online October 13, 2021
DOI: https://doi.org/10.4143/crt.2021.674
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare the treatment outcomes of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT) for colorectal cancer liver metastases (CRLM) and to determine the favorable treatment modality according to tumor characteristics.
Materials and Methods
We retrospectively analyzed the records of 222 colorectal cancer patients with 330 CRLM who underwent RFA (268 tumors in 178 patients) or SBRT (62 tumors in 44 patients) between 2007 and 2014. Kaplan–Meier method and Cox models were used by adjusting with inverse probability of treatment weighting (IPTW).
Results
The median follow-up duration was 30.5 months. The median tumor size was significantly smaller in the RFA group than in the SBRT group (1.5 cm vs 2.3 cm, p<0.001). In IPTW-adjusted analysis, difference in treatment modality was not associated with significant differences in 1-year and 3-year recurrence-free survival (35% vs 43%, 22% vs 23%; p=0.198), overall survival (96% vs 91%, 58% vs 56%; p=0.508), and freedom from local progression (FFLP; 90% vs 72%, 78% vs 60%; p=0.106). Significant interaction effect between the treatment modality and tumor size was observed for FFLP (p=0.001). In IPTW-adjusted subgroup analysis of patients with tumor size >2 cm, the SBRT group had a higher FFLP compared with the RFA group (HR, 0.153; p<0.001).
Conclusion
SBRT and RFA showed similar local control in the treatment of patients with CRLM. Tumor size was an independent prognostic factor for local control and SBRT may be preferred for larger tumors.

Citations

Citations to this article as recorded by  
  • Treatment of Oligometastatic GI Cancers
    Clayton T. Marcinak, Patrick B. Schwartz, Mustafa M. Basree, Newton Hurst, Michael Bassetti, Jeremy D. Kratz, Nataliya V. Uboha
    American Society of Clinical Oncology Educational Book.2024;[Epub]     CrossRef
  • Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations
    D. Pezzulla, G. Chiloiro, E. M. Lima, G. Macchia, C. Romano, S. Reina, G. Panza, S. Cilla, A. G. Morganti, F. Cellini, M. A. Gambacorta, F. Deodato
    Clinical & Experimental Metastasis.2024; 41(5): 667.     CrossRef
  • Interventionelle Therapieoptionen bei oligometastasierten Tumoren
    Max Seidensticker
    Forum.2024; 39(5): 340.     CrossRef
  • Efficacy and safety of B-ultrasound-guided radiofrequency ablation in the treatment of primary liver cancer: Systematic review and meta-analysis
    Xiong Zhang, Hong-Yi Zhu, Ming Yuan
    World Journal of Gastrointestinal Surgery.2024; 16(9): 2986.     CrossRef
  • Analysis of alkaline phosphatase and γ-glutamyltransferase after radiofrequency ablation of primary liver cancer: A retrospective study
    Wen-Yu Huang, Sheng Zheng, Dan Zhu, Ying-Lang Zeng, Juan Yang, Xue-Li Zeng, Pei Liu, Shun-Ling Zhang, Ming Yuan, Zhi-Xia Wang
    World Journal of Gastrointestinal Surgery.2024; 16(9): 2860.     CrossRef
  • Recent trends in radiotherapy use for major cancers in Korea
    Kyungmi Yang, Jeong Eun Lee, Won Park, Yong Chan Ahn, Seung Jae Huh
    Japanese Journal of Clinical Oncology.2023; 53(12): 1177.     CrossRef
  • Combination of endoscopic ultrasound-guided radiofrequency ablation and adaptive radiation therapy for the treatment of lymph node metastases from colon adenocarcinoma: A case report
    Federica Borrelli de Andreis, Maria Alessandra Calegari, Angela Romano, Maria Gabriella Brizi, Luigi Sofo, Ivo Boskoski, Guido Costamagna, Fabia Attili
    Current Problems in Cancer: Case Reports.2023; 9: 100216.     CrossRef
  • Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis
    Chai Hong Rim, Jung Sue Lee, Soo Yeon Kim, Jinsil Seong
    JHEP Reports.2023; 5(1): 100594.     CrossRef
  • Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
    Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee
    Cancer Research and Treatment.2023; 55(3): 707.     CrossRef
  • Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century
    Sara Mheid, Stefan Allen, Sylvia S. W. Ng, William A. Hall, Nina N. Sanford, Todd A. Aguilera, Ahmed M. Elamir, Rana Bahij, Martijn P. W. Intven, Ganesh Radhakrishna, Issa Mohamad, Jeremy De Leon, Hendrick Tan, Shirley Lewis, Cihan Gani, Teo Stanecu, Vero
    Current Oncology.2023; 30(10): 9230.     CrossRef
  • Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade
    Koji Tomita, Yusuke Matsui, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Kazuaki Munetomo, Shoma Nagata, Toshihiro Iguchi, Takao Hiraki
    Japanese Journal of Radiology.2022; 40(10): 1035.     CrossRef
  • 8,535 View
  • 283 Download
  • 10 Web of Science
  • 11 Crossref
Close layer
Association of Body Mass Index with Survival in Asian Patients with Colorectal Cancer
Sangwon Lee, Dong Hee Lee, Jae-Hoon Lee, Su-Jin Shin, Hye Sun Lee, Eun Jung Park, Seung Hyuk Baik, Kang Young Lee, Jeonghyun Kang
Cancer Res Treat. 2022;54(3):860-872.   Published online October 15, 2021
DOI: https://doi.org/10.4143/crt.2021.656
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The clinical significance of body mass index (BMI) on long-term outcomes has not been extensively investigated in Asian patients with colorectal cancer (CRC). This study aims to describe the association between BMI and survival, plus providing BMI cut-off value for predicting prognosis in CRC patients.
Materials and Methods
A total of 1,182 patients who had undergone surgery for stage I-III CRC from June 2004 to February 2014 were included. BMI was categorized into four groups based on the recommendation for Asian ethnicity. The optimal BMI cut-off value was determined to maximize overall survival (OS) difference.
Results
In multivariable analysis, underweight BMI was significantly associated with poor OS (hazard ratio [HR], 2.38; 95% confidence interval [CI], 1.55 to 3.71; p < 0.001) and obese BMI was associated with better OS (HR, 0.72; 95% CI, 0.53 to 0.97; p=0.036) compared with the normal BMI. Overweight and obese BMI were associated with better recurrence-free survival (HR, 0.64; 95% CI, 0.42 to 0.99; p=0.046 and HR, 0.58; 95% CI, 0.38 to 0.89; p=0.014, respectively) compared with the normal BMI group. BMI cutoff value was 20.44 kg/m2. Adding the BMI cutoff value to cancer staging could increase discriminatory performance in terms of integrated area under the curve and Harrell’s concordance index.
Conclusion
Compared to normal BMI, underweight BMI was associated with poor survival whereas obese BMI was associated with better survival. BMI cut-off value of 20.44 kg/m2 is a useful discriminator in Asian patients with CRC.

Citations

Citations to this article as recorded by  
  • Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies
    H. Wen, G. Deng, X. Shi, Z. Liu, A. Lin, Q. Cheng, J. Zhang, P. Luo
    ESMO Open.2024; 9(3): 102241.     CrossRef
  • Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle–Income Country Setting
    Kirati Kengkla, Surakit Nathisuwan, Warunsuda Sripakdee, Pirun Saelue, Kwanruethai Sengnoo, Aumkhae Sookprasert, Suphat Subongkot
    JCO Global Oncology.2024;[Epub]     CrossRef
  • Post‐diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis
    Nerea Becerra‐Tomás, Georgios Markozannes, Margarita Cariolou, Katia Balducci, Rita Vieira, Sonia Kiss, Dagfinn Aune, Darren C. Greenwood, Laure Dossus, Ellen Copson, Andrew G. Renehan, Martijn Bours, Wendy Demark‐Wahnefried, Melissa M. Hudson, Anne M. Ma
    International Journal of Cancer.2024; 155(3): 400.     CrossRef
  • Low muscle mass-to-fat ratio is an independent factor that predicts worse overall survival and complications in patients with colon cancer: a retrospective single-center cohort study
    Jiabao Tang, Jingwen Xu, Xiaohua Li, Chun Cao
    Annals of Surgical Treatment and Research.2024; 107(2): 68.     CrossRef
  • Obesity, the Adipose Organ and Cancer in Humans: Association or Causation?
    Elisabetta Trevellin, Silvia Bettini, Anna Pilatone, Roberto Vettor, Gabriella Milan
    Biomedicines.2023; 11(5): 1319.     CrossRef
  • Higher body mass index was associated with better prognosis in diabetic patients with stage II colorectal cancer
    Xiao-Yu Liu, Bing Kang, Yu-Xi Cheng, Chao Yuan, Wei Tao, Bin Zhang, Zheng-Qiang Wei, Dong Peng
    BMC Cancer.2022;[Epub]     CrossRef
  • Preoperative carcinoembryonic antigen to body mass index ratio contributes to prognosis prediction in colorectal cancer
    Jia Xiang, Mengyao Ding, Jixing Lin, Tianhui Xue, Qianwen Ye, Bing Yan
    Oncology Letters.2022;[Epub]     CrossRef
  • 7,155 View
  • 135 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Daily Vigorous Intensity Physical Activity and Its Preventive Effect on Pancreatic Cancer
Sung Keun Park, Ju Young Jung, Chang-Mo Oh, Min-Ho Kim, Eunhee Ha, Yeji Kim, Do Jin Nam, Jae-Hong Ryoo
Cancer Res Treat. 2022;54(3):873-881.   Published online September 27, 2021
DOI: https://doi.org/10.4143/crt.2021.400
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There has been accumulating evidence for the preventive effect of high physical activity on cancer. However, it is still unclear which level of physical activity is associated with the decreased risk of pancreatic cancer. The purpose of current study is to assess the association between the frequency of vigorous intensity physical activity and the risk of pancreatic cancer.
Materials and Methods
The nationwide retrospective cohort study was conducted using the National Health Information Database. Study participants were 220,357 Koreans who received health check-up in 2009. They were divided into four groups by the weekly frequency of vigorous intensity physical activity longer than 20 minutes (group 1, no vigorous intensity physical activity (reference); group 2, 1-3 days; group 3, 4-5 days and group 4, 6-7 days). Cox proportional hazard model was used to calculate the adjusted hazard ratios (HRs) and 95% confidence interval (CI) for incident pancreatic cancer (adjusted HRs [95% CI]) according to the weekly frequency of vigorous intensity physical activity.
Results
For 4.38 years’ follow-up on average, 377 cases of pancreatic cancer developed. Subjects without incident pancreatic cancer had more favorable metabolic condition and higher physical activity than subjects with incident pancreatic cancer. Adjusted HRs and 95% CI indicated that only group 4 was significantly associated with the decreased risk of pancreatic cancer (group 1, reference; group 2, 1.10 [0.86-1.40]; group 3, 0.75 [0.45-1.25] and group 4, 0.47 [0.25-0.89]).
Conclusion
In this nationwide representative cohort study, near daily vigorous intensity physical activity showed the preventive effect on pancreatic cancer.

Citations

Citations to this article as recorded by  
  • Association between waist circumference change after smoking cessation and incidence of hypertension in Korean adults
    H.J. Lee, J.W. Choi
    Public Health.2024; 229: 73.     CrossRef
  • Physical Activity Decreases Inflammation and Delays the Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma
    Valentina Pita-Grisanti, Ericka Velez-Bonet, Kaylin Chasser, Zachary Hurst, Alexus Liette, Grace Vulic, Kelly Dubay, Ali Lahooti, Niharika Badi, Olivia Ueltschi, Kristyn Gumpper-Fedus, Hsiang-Yin Hsueh, Ila Lahooti, Myrriah Chavez-Tomar, Samantha Terhorst
    Cancer Research.2024; 84(18): 3058.     CrossRef
  • The role of exercise in obesity-related cancers: Current evidence and biological mechanisms
    Elisabeth A. Larson, Maria Dalamaga, Faidon Magkos
    Seminars in Cancer Biology.2023; 91: 16.     CrossRef
  • Effect of physical activity on incidence and mortality in patients with gastric cancer: evidence from real-world studies
    Shaodi Ma, Haixia Liu, Chenyu Sun, Muzi Meng, Guangbo Qu, Yuemeng Jiang, Birong Wu, Juan Gao, Linya Feng, Peng Xie, Weihang Xia, Yehuan Sun
    Cancer Causes & Control.2023; 34(12): 1095.     CrossRef
  • Integrated procedures for accelerating, deepening, and leading genetic inquiry: A first application on human muscle secretome
    Danilo Bondi, Michele Bevere, Rosanna Piccirillo, Guglielmo Sorci, Valentina Di Felice, Andrea David Re Cecconi, Daniela D'Amico, Tiziana Pietrangelo, Stefania Fulle
    Molecular Genetics and Metabolism.2023; 140(3): 107705.     CrossRef
  • 6,232 View
  • 135 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Genitourinary cancer
Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis
Jungyo Suh, Dohyun Han, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak, Chang Wook Jeong
Cancer Res Treat. 2022;54(3):882-893.   Published online October 9, 2021
DOI: https://doi.org/10.4143/crt.2021.642
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to identify, verify, and validate a multiplex urinary biomarker-based prediction model for diagnosis and surveillance of urothelial carcinoma of bladder, using high-throughput proteomics methods.
Materials and Methods
Label-free quantification of data-dependent and data-independent acquisition of 12 and 24 individuals was performed in each of the discovery and verification phases using mass spectrometry, simultaneously using urinary exosome and proteins. Based on five scoring system based on proteomics data and statistical methods, we selected eight proteins. Enzyme-linked immunosorbent assay on urine from 120 patients with bladder mass lesions used for validation. Using multivariable logistic regression, we selected final candidate models for predicting bladder cancer.
Results
Comparing the discovery and verification cohorts, 38% (50/132 exosomal differentially expressed proteins [DEPs]) and 44% (109/248 urinary DEPs) are consistent at statistically significance, respectively. The 20 out of 50 exosome proteins and 27 out of 109 urinary proteins were upregulated in cancer patients. From eight selected proteins, we developed two diagnostic models for bladder cancer. The area under the receiver operating characteristic curve (AUROC) of two models were 0.845 and 0.842, which outperformed AUROC of urine cytology.
Conclusion
The results showed that the two diagnostic models developed here were more accurate than urine cytology. We successfully developed and validated a multiplex urinary protein-based prediction, which will have wide applications for the rapid diagnosis of urothelial carcinoma of the bladder. External validation for this biomarker panel in large population is required.

Citations

Citations to this article as recorded by  
  • A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes
    Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
    eLife.2024;[Epub]     CrossRef
  • A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes
    Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
    eLife.2024;[Epub]     CrossRef
  • Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer
    Qi Chang, Yongqiang Chen, Jianjian Yin, Tao Wang, Yuanheng Dai, Zixin Wu, Yufeng Guo, Lingang Wang, Yufen Zhao, Hang Yuan, Dongkui Song, Lirong Zhang
    Journal of Proteome Research.2024; 23(6): 2241.     CrossRef
  • Construction of noninvasive prognostic model of bladder cancer patients based on urine proteomics and screening of natural compounds
    Shun Wan, Jinlong Cao, Siyu Chen, Jianwei Yang, Huabin Wang, Chenyang Wang, Kunpeng Li, Li Yang
    Journal of Cancer Research and Clinical Oncology.2023; 149(1): 281.     CrossRef
  • Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
    Ana Teixeira-Marques, Catarina Lourenço, Miguel Carlos Oliveira, Rui Henrique, Carmen Jerónimo
    International Journal of Molecular Sciences.2023; 24(7): 6757.     CrossRef
  • Advances in the application of label‐free quantitative proteomics techniques in malignancy research
    Xiao Meng, Dong Liu, Yan Guan
    Biomedical Chromatography.2023;[Epub]     CrossRef
  • Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer
    Jiaxin Zhao, Jinming Li, Rui Zhang
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(4): 188926.     CrossRef
  • An overview of metabolomic and proteomic profiling in bipolar disorder and its clinical value
    Henrique Caracho Ribeiro, Flávia da Silva Zandonadi, Alessandra Sussulini
    Expert Review of Proteomics.2023; 20(11): 267.     CrossRef
  • Proteome and immune responses of extracellular vesicles derived from macrophages infected with the periodontal pathogen Tannerella forsythia
    Younggap Lim, Hyun Young Kim, Dohyun Han, Bong‐Kyu Choi
    Journal of Extracellular Vesicles.2023;[Epub]     CrossRef
  • A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers
    Milena Matuszczak, Adam Kiljańczyk, Maciej Salagierski
    International Journal of Molecular Sciences.2022; 23(15): 8597.     CrossRef
  • Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19
    Takahiro Kawasaki, Yoshito Takeda, Ryuya Edahiro, Yuya Shirai, Mari Nogami-Itoh, Takanori Matsuki, Hiroshi Kida, Takatoshi Enomoto, Reina Hara, Yoshimi Noda, Yuichi Adachi, Takayuki Niitsu, Saori Amiya, Yuta Yamaguchi, Teruaki Murakami, Yasuhiro Kato, Tak
    Inflammation and Regeneration.2022;[Epub]     CrossRef
  • 7,917 View
  • 274 Download
  • 10 Web of Science
  • 11 Crossref
Close layer
Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
Ryul Kim, Jung Yong Hong, Jeeyun Lee, Ghee Young Kwon, Byong Chang Jeong, Se Hoon Park
Cancer Res Treat. 2022;54(3):894-906.   Published online November 17, 2021
DOI: https://doi.org/10.4143/crt.2021.854
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI).
Materials and Methods
We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8).
Results
We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1–positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1–negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1–positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1–positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment.
Conclusion
Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.

Citations

Citations to this article as recorded by  
  • The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy
    Li-Juan Chen, Xin-Yang Xu, Xiao-Dan Zhong, Yan-Jun Liu, Ming-Hui Zhu, Fan Tao, Chang-Yun Li, Qiu-Sheng She, Guan-Jun Yang, Jiong Chen
    Bioorganic Chemistry.2023; 133: 106409.     CrossRef
  • A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma
    Zheng Zhou, Yusong Zhou, Wei Liu, Jing Dai
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Implication of KDM6A in Bladder Cancer
    Marianne Matar, Gilles Prince, Ibrahim Hamati, Maria Baalbaky, Jonas Fares, Marc Aoude, Charbel Matar, Hampig Raphael Kourie
    Pharmacogenomics.2023; 24(9): 509.     CrossRef
  • Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
    Biomedicines.2022; 10(8): 2005.     CrossRef
  • Antineoplastics

    Reactions Weekly.2022; 1933(1): 61.     CrossRef
  • Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma
    Tongjin Xie, Bin Liu, Dongbo Liu, Yusong Zhou, Qingping Yang, Dai Wang, Mengjie Tang, Wei Liu
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • 7,301 View
  • 244 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Pediatric cancer
Chronological Analysis of Acute Hematological Outcomes after Proton and Photon Beam Craniospinal Irradiation in Pediatric Brain Tumors
Gyu Sang Yoo, Jeong Il Yu, Sungkoo Cho, Youngyih Han, Yoonjin Oh, Do Hoon Lim, Hee Rim Nam, Ji-Won Lee, Ki-Woong Sung, Hyung Jin Shin
Cancer Res Treat. 2022;54(3):907-916.   Published online October 15, 2021
DOI: https://doi.org/10.4143/crt.2021.332
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare the early hematological dynamics and acute toxicities between proton beam craniospinal irradiation (PrCSI) and photon beam craniospinal irradiation (PhCSI) for pediatric brain tumors.
Materials and Methods
We retrospectively reviewed patients with pediatric brain tumors who received craniospinal irradiation (CSI). The average change in hemoglobin levels (ΔHbavg), absolute lymphocyte counts (ΔALCavg), and platelet counts (ΔPLTavg) from baseline values was evaluated and compared between the PrCSI and PhCSI groups at 1 and 2 weeks after the initiation of CSI, 1 week before and at the end of radiotherapy, and 3-4 weeks after the completion of radiotherapy using t test and mixed-model analysis.
Results
The PrCSI and PhCSI groups consisted of 36 and 30 patients, respectively. There were no significant differences in ΔHbavg between the two groups at any timepoint. However, ΔALCavg and ΔPLTavg were significantly lower in the PhCSI group than in PrCSI group at every timepoint, demonstrating that PrCSI resulted in a significantly lower rate of decline and better recovery of absolute lymphocyte and platelet counts. The rate of grade 3 acute anemia was significantly lower in the PrCSI group than in in the PhCSI group.
Conclusion
PrCSI showed a lower rate of decline and better recovery of absolute lymphocyte and platelet counts than PhCSI in the CSI for pediatric brain tumors. Grade 3 acute anemia was significantly less frequent in the PrCSI group than in the PhCSI group. Further large-scale studies are warranted to confirm these results.

Citations

Citations to this article as recorded by  
  • Long-term effects of local radiotherapy on growth and vertebral features in children with high-risk neuroblastoma
    Kyungmi Yang, Joong Hyun Ahn, Sook-Young Woo, Sang Hoon Jung, Ki Woong Sung, Ji Won Lee, Do Hoon Lim
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Comparison of Craniospinal Irradiation Using Proton Beams According to Irradiation Method and Initial Experience Treating Pediatric Patients
    Nobuyoshi Fukumitsu, Hikaru Kubota, Masayuki Mima, Yusuke Demizu, Takeshi Suzuki, Daiichiro Hasegawa, Yoshiyuki Kosaka, Atsufumi Kawamura, Toshinori Soejima
    Advances in Radiation Oncology.2023; 8(5): 101251.     CrossRef
  • Proton versus photon radiation therapy: A clinical review
    Zhe Chen, Michael M. Dominello, Michael C. Joiner, Jay W. Burmeister
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Shifting Strategies in the Treatment of Pediatric Craniopharyngioma
    Segev Gabay, Thomas E. Merchant, Frederick A. Boop, Jonathan Roth, Shlomi Constantini
    Current Oncology Reports.2023; 25(12): 1497.     CrossRef
  • 5,552 View
  • 132 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse
Xinyu Wan, Xiaomin Yang, Fan Yang, Tianyi Wang, Lixia Ding, Lili Song, Yan Miao, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Yanjing Tang, Jun Lu, Benshang Li
Cancer Res Treat. 2022;54(3):917-925.   Published online September 17, 2021
DOI: https://doi.org/10.4143/crt.2021.399
AbstractAbstract PDFPubReaderePub
Purpose
Anti-CD19 chimeric antigen receptor T-cell immunotherapy (19CAR-T) has achieved impressive clinical results in adult and pediatric relapsed/refractory (r/r) B-lineage acute lymphoblastic leukemia (B-ALL). However, the application and effect of CAR-T therapy in B-ALL patients with extramedullary relapse are rarely issued even disqualified in some clinical trials. Here, we examined the efficacy of 19CAR-T in patients with both bone marrow and extramedullary involvement.
Materials and Methods
CAR-T cells were generated by transfection of primary human T lymphocytes with a lentiviral vector expressing anti-CD19 single chain antibody fragments (scFvs) with the cytoplasmic domains of 4-1BB and CD3ζ, and used to infuse patients diagnosed as having r/r B-ALL with extramedullary origination. Clinical responses were evaluated by the use of bone marrow aspiration, imaging, and flow cytometry.
Results
Eight patients received 19CAR-T infusion and all attained complete remission (CR). Only one patient was bridged to hematopoietic stem cell transplantation (HSCT). Although three patients relapsed after infusion, they received 19/22CAR-T infusion sequentially and attained a second remission. To date, five patients are in continuous CR and all eight patients are still alive. The mean follow-up time was 21.9 months, while the 24-month estimated event-free survival is 51.4%.
Conclusion
19CAR-T therapy can lead to clinical remission for extramedullary relapsed pediatric B-ALL patients. However, the problem of CD19+ relapses after CAR-T remained to be solved. For patients relapsing after CAR-T, a second CAR-T therapy creates another opportunity for remission for subsequent HSCT.

Citations

Citations to this article as recorded by  
  • Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
    Alexandra Dreyzin, Alexander W. Rankin, Katia Luciani, Tatyana Gavrilova, Nirali N. Shah
    Expert Review of Clinical Immunology.2024; 20(7): 745.     CrossRef
  • Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia
    Lijuan Wu, Junchao Chen, Ruifen Cai, Xinrui Wang, Yixiao Liu, Qingshan Zheng, Lujin Li
    Cancers.2023; 15(10): 2767.     CrossRef
  • Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review
    Franco Locatelli, Bijal Shah, Tracy Thomas, Kelly Velasco, Babatunde Adedokun, Ibrahim Aldoss, Lia Gore, Dieter Hoelzer, Renato Bassan, Jae H. Park, Nicolas Boissel, Hagop Kantarjian
    Leukemia & Lymphoma.2023; 64(10): 1615.     CrossRef
  • Using the Power of Junctional Adhesion Molecules Combined with the Target of CAR-T to Inhibit Cancer Proliferation, Metastasis and Eradicate Tumors
    Christopher Mendoza, Dario Mizrachi
    Biomedicines.2022; 10(2): 381.     CrossRef
  • Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
    Elizabeth M. Holland, Bonnie Yates, Alex Ling, Constance M. Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Michael LaLoggia, John C. Molina, Daniel A. Lichtenstein, Daniel W. Lee, John A. Ligon, Haneen Shalabi, Mark A. Ahlman, Nirali N. Shah
    Blood Advances.2022; 6(7): 2167.     CrossRef
  • Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse
    Luo HUANG, Mingming ZHANG, Guoqing WEI, Houli ZHAO, Yongxian HU, He HUANG
    Journal of Zhejiang University (Medical Sciences).2022; 51(2): 151.     CrossRef
  • Results of ARI‐0001 CART19 cell therapy in patients with relapsed/refractory CD19‐positive acute lymphoblastic leukemia with isolated extramedullary disease
    Valentín Ortiz‐Maldonado, Anna Alonso‐Saladrigues, Marta Español‐Rego, Nuria Martínez‐Cibrián, Anna Faura, Laura Magnano, Albert Català, Daniel Benítez‐Ribas, Eva Giné, Marina Díaz‐Beyá, Juan Gonzalo Correa, Montserrat Rovira, Mercedes Montoro‐Lorite, Ale
    American Journal of Hematology.2022; 97(6): 731.     CrossRef
  • Umbilical cord blood: A promising source for allogeneic CAR-T cells
    Dian-Dian Liu, Wei-Cong Hong, Kun-Yin Qiu, Xin-Yu Li, Yong Liu, Li-Wen Zhu, Wei-Xin Lai, Han- Chen, Hua-Qing Yang, Lu-Hong Xu, Jian-Pei Fang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
    Sabine Kayser, Chiara Sartor, Marlise R. Luskin, Jonathan Webster, Fabio Giglio, Nydia Panitz, Andrew M. Brunner, Matthias Fante, Christoph Lutz, Daniel Wolff, Anthony D. Ho, Mark J. Levis, Richard F. Schlenk, Cristina Papayannidis
    Haematologica.2022; 107(9): 2064.     CrossRef
  • 6,961 View
  • 214 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Hematologic malignancy
Association between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea
Taewoong Choi, Wooin Ahn, Dong Wook Shin, Kyungdo Han, Dahye Kim, Sohyun Chun
Cancer Res Treat. 2022;54(3):926-936.   Published online September 27, 2021
DOI: https://doi.org/10.4143/crt.2021.951
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
While renal impairment is one of the first clinical manifestations of multiple myeloma (MM), declined renal function may conversely be a risk factor for cancers including MM. In this study, we investigated the relationship between chronic kidney disease and MM at a population level.
Materials and Methods
A total of 9,809,376 adults who participated in a nationwide health screening program and had no MM, cancer or end-stage renal disease at baseline were investigated for incidence of MM. The impact of estimated glomerular filtration rate (eGFR) and random urine dipstick proteinuria, and interactive associations of the two factors on the MM incidence were evaluated.
Results
The general incidence of MM was 4.8 per 100,000 person-years (mean follow-up of 8.3 years). Participants with eGFR < 60 mL/min/1.73 m2 (5.8% of participants) had higher MM incidence than those with eGFR ≥ 60 mL/min/1.73 m2 (adjusted hazard ratio, 1.29; 95% confidence interval, 1.17 to 1.43). When eGFR was graded into five levels, there was a significant inverse dose-response relationship between eGFR level and MM incidence at the lower eGFR levels (reference: eGFR 60-89 mL/min/1.73 m2). A dose-response relationship was also found with degree of dipstick proteinuria and incidence of MM.
Conclusion
Adults with decreased renal function indicated either by decreased eGFR or presence of proteinuria are at a higher risk of developing MM compared to those without, and there is a dose-response relationship between the severity of renal impairment and MM incidence.

Citations

Citations to this article as recorded by  
  • Quantitative risk factor analysis of prior disease condition and socioeconomic status with the multiple myeloma development: nationwide cohort study
    Suein Choi, Eunjin Kim, Jinhee Jung, Sung-Soo Park, Chang-Ki Min, Seunghoon Han
    Scientific Reports.2024;[Epub]     CrossRef
  • 6,999 View
  • 142 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Skin cancer
Incidence and Survival Rates of Cutaneous Melanoma in South Korea Using Nationwide Health Insurance Claims Data
TaeHo Kim, Siyeong Yoon, Dong-Eun Shin, Sang Cheol Lee, Jisu Oh, So-Young Lee, Do Kyung Kim, Segi Kim, Bosung Jung, Minsup Kim, Soonchul Lee
Cancer Res Treat. 2022;54(3):937-949.   Published online September 30, 2021
DOI: https://doi.org/10.4143/crt.2021.871
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Melanoma incidence is rising worldwide along with the associated personal and socioeconomic health expenditures. We investigated the incidence and survival-rate patterns of melanoma in South Korea using nationwide data.
Materials and Methods
This retrospective cohort study included patients with melanoma between 2004 and 2017, based on National Health Insurance (NHI) claims data in South Korea. The incidence, prevalence, and survival rate were analyzed along with baseline demographic characteristics. We collected solar irradiation dose (SID) and healthcare ranking score (HRS) according to the administrative district from the Korea Meteorological Administration and Korea Health Promotion Institute. The incidence and survival rates were assessed using Pearson's correlation, the Kaplan-Meier estimation, multiple linear regression, and multiple logistic regression methods.
Results
Twenty-five thousand, five hundred ninety-one patients with melanoma were diagnosed during the study period. The age-standardized incidence of melanoma steadily increased from 2004 to 2017 from 2.6 to 3.0/100,000/yr. The incidence of melanoma increased with significantly higher income (p < 0.05). The prevalence followed a similar pattern as the incidence. According to multivariate analysis, HRS significantly influenced the incidence of melanoma in high sun-exposed sites (p < 0.001). There was no significant change in annual mortality. Women had a higher 5-year survival rate than men (78.4% vs. 72.8%). Mortality by the administrative district was highly correlated with HRS.
Conclusion
The incidence of melanoma is increasing in South Korea. A low HRS is associated with both higher incidence and mortality. The findings of this study could be utilized as a guideline for treating melanoma patients.

Citations

Citations to this article as recorded by  
  • Incidence and survival rates of primary cutaneous malignancies in Korea, 1999–2019: A nationwide population‐based study
    Soon‐Hyo Kwon, Sangmin Choi, Joung Soo Kim, Sang Seok Kim, Mihn‐Sook Jue, Soo Hong Seo, Jihye Park, Mi Ryung Roh, Je‐Ho Mun, Jun Young Kim, Jee Woong Choi, Ji Won Byun, Sanghyun Park, Min Sung Kim, Seok‐Jong Lee
    The Journal of Dermatology.2024; 51(4): 532.     CrossRef
  • The Effect of Interval Training and Urtica Dioica Hydroalcoholic Extract on some Growth and Immune Factors in C57 Rats with Melanoma Cancer
    Maryam Firoozi, Alireza Barari, Asieh Abbassi Daloii, Hossein Abednatanzi
    Complementary Medicine Journal.2024; 13(4): 44.     CrossRef
  • Hellebrigenin induces apoptosis by triggering cellular inhibitor of apoptosis 1 and Jun N-terminal kinase pathway in melanoma cells
    Mu-Kuei Shieu, Yi-Ching Chuang, Hsin-Yu Ho, Chia-Chieh Lin, Yu-Sheng Lo, Ming-Ju Hsieh
    Dermatologica Sinica.2024; 42(1): 19.     CrossRef
  • Analyses of Osteogenesis Imperfecta in South Korea Using the Nationwide Health Insurance Service Claim Data: A Propensity Score-Matched Study
    Sin Hyung Park, Ho Yoon, Siyeong Yoon, Jaiwoo Chung, Jae-hyun Kim, Soonchul Lee
    Calcified Tissue International.2024;[Epub]     CrossRef
  • Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea
    Isaac Kim, Jisu Oh, Siyeoung Yoon, Man-Yong Han, Jaiwoo Chung, Younghoon Jung, Hyun-Il Lee, Soonchul Lee
    Melanoma Research.2024; 34(6): 528.     CrossRef
  • The effects of exposure to solar radiation on human health
    R. E. Neale, R. M. Lucas, S. N. Byrne, L. Hollestein, L. E. Rhodes, S. Yazar, A. R. Young, M. Berwick, R. A. Ireland, C. M. Olsen
    Photochemical & Photobiological Sciences.2023; 22(5): 1011.     CrossRef
  • Survival rates for invasive cutaneous malignant melanoma in South Korea in accordance with the Eighth edition AJCC Cancer Staging Manual: A retrospective single center study
    Seon Hwa Lee, Gi Ung Ha, Hyun Ji Lee, Ho Yun Chung, Seung Huh, Dae-Lyong Ha, Kyung Duck Park, Yong Hyun Jang, Weon Ju Lee, Seok-Jong Lee, Jun Young Kim
    Indian Journal of Dermatology, Venereology and Leprology.2023; 0: 1.     CrossRef
  • Clinicopathological characteristics and prognosis of Merkel cell carcinoma: a single-center retrospective study in Korea
    Ik Jun Moon, Hyungmin Na, Hye Soo Cho, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10065.     CrossRef
  • 9,173 View
  • 205 Download
  • 6 Web of Science
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP